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ABSTRACT
Putative Role of Palmitate and Akt signaling in Attenuating Skeletal Muscle Growth in the
Obese Zucker Rat
Jonathan Michael Peterson, BS, MS

The Obese zucker rat (OZR) is a model of obesity and metabolic syndrome, with a
reduced skeletal muscle mass compared with the lean zucker rat (LZR). Growth and hypertrophy
of muscle fibers critically depend on activation and differentiation of satellite cells into new
myonuclei, as well as the prevention of myonuclear apoptosis. Akt is known to regulate satellite
cell activation and differentiation and inhibit apoptotic signaling. Akt activity is also reduced in
the OZR compared to the LZR. The present study had two primary purposes; first, to observe, in
vitro, the effects of the saturated free fatty acid palmitate on C2C12 mouse myoblast
proliferation and differentiation, Akt signaling and apoptosis in myotubes, and second, to
examine if there was reduced Akt signaling, satellite cell proliferation and differentiation, and/or
increased satellite death in the OZR compared to the LZR. Akt signaling was significantly
reduced both in vitro following palmitate treatment and in vivo in the OZR. Furthermore,
myoblast proliferation and differentiation were reduced after palmitate treatment, in vitro, and
satellite cell activation was reduced in the OZR compared to the LZR. Although palmitate
treatment was sufficient to induce apoptotic signaling in C2C12 myotubes, there was no increase
in apoptotic signaling in muscles of the OZR. Together, these data indicate that although
disruptions in Akt signaling in muscles of the OZR may be responsible for the decrease in
muscle mass through attenuated satellite cell activation and proliferation, increased apoptotic
signaling does not appear to be a factor to explain the decrease muscle mass in the OZR
compared to the LZR.
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SPECIFIC AIMS
Metabolic syndrome is a clinically important problem, which affect more than 50 million
Americans (11). Metabolic syndrome is defined as a cluster of risk factors for heart disease and
type 2 diabetes mellitus including: (i) obesity, (ii) insulin resistance (with or without glucose
intolerance), (iii) hypertension, (iv) dyslipidemia, (v) a prothrombotic state (e.g., high fibrinogen
or plasminogen activator inhibitor–1 in the blood), and (vi) a proinflammatory state (e.g.,
elevated C-reactive protein in the blood). Disruptions of glucose or fatty acid oxidation are major
contributors to the complications associated with obesity and metabolic syndrome. Because
skeletal muscles are the primary tissue responsible for glucose and fatty acid oxidation (2; 3; 23),
any reduced skeletal muscle mass would be an unfavorable outcome in metabolic syndrome.
The obese Zucker (fa/fa) rat (OZR) is a rodent model of severe obesity and metabolic
syndrome. The OZR has a dysfunctional leptin receptor which leads to chronic hyperphagia,
resulting in a rapid onset of obesity, skeletal muscle insulin resistance, hyperglycemia, mild
hypertension, and high circulating levels of free fatty acids (12; 26; 27; 30). Although OZRs are
significantly less active than the LZRs (5), OZRs have a greater body mass, and therefore should
have a greater stimulus for muscle growth on the weight bearing muscles. However, there is a
significant (10-25%) reduction in the skeletal muscle mass of the OZR compared to the lean
Zucker rat (LZR) phenotype (10). We have found that increasing the activity of the OZR through
daily treadmill running, fails to increase the size of skeletal muscles (12). This raises the
possibility that a metabolic syndrome induced defect in skeletal muscle may account for the
reduction in skeletal muscle mass in the OZR.
Hypertrophy of muscle fibers critically depends on the activation and differentiation of
satellite cells into new myonuclei, as well as the preservation of mature myonuclei (1; 17; 21; 22;
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24). It is possible that disruptions in the regulation of myonuclear number may account for the
reduced muscle mass in the OZR compared to the LZR, as muscle fiber size is critically
dependent on myonuclear content (1; 24). This idea is consistent with the observation that
nucleic acid content is less in the OZR, (10) which could be explained if there was a decreased
myonuclear number, in the skeletal muscles of OZRs compared to the LZRs.
One potential mechanism that might account for reduced nuclei is lower Akt activity in
muscles of the OZR (20). This is because Akt regulates at least in part, satellite cell activation
and differentiation, and inhibits myonuclear apoptosis (4; 8; 9; 13-15; 18; 19; 25; 28; 29). Akt
activity might be inhibited by high intramuscular lipid levels in muscles of animals with
metabolic syndrome, such as palmitate (6; 7), which is the most common saturated fatty acid
found in the muscle tissue (16). Our central hypothesis is that increased palmitate decreases
satellite cell proliferation and differentiation and sensitizes differentiated myonuclei to
apoptosis through disruptions in Akt signaling. This central hypothesis was tested by the
following four specific aims.

Specific aim 1: To determine if the addition of palmitate attenuates proliferation and
differentiation of myoblasts in vitro.
Hypothesis 1.1: Palmitate treatment of C2C12 myoblasts will decrease myoblast
proliferation in vitro.
Hypothesis 1.2: Palmitate treatment will reduce myoblast fusion/ differentiation in vitro.
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Specific aim 2: To determine if reduced proliferation and differentiation of satellite cells
contributes to a decreased muscle fiber size and muscle wet weight in the OZR model of obesity
and metabolic syndrome.
Hypothesis 2.1: The number of activated satellite cells incorporated into myofibers in
vivo will be lower in muscles of OZR rats compared to LZR.
Hypothesis 2.2: Impaired satellite cell proliferation cannot be restored by increased
loading in skeletal muscles of OZR compared to the LZR.

Specific aim 3: To determine if palmitate treatment increases the susceptibly of myoblasts or
myotubes to mitochondrial-associated apoptosis in vitro.
Hypothesis 3.1: Palmitate treatment will increase nuclear apoptosis of C2C12 myoblasts
and myotubes through mitochondrial-associated (intrinsic) pathways including an
elevation of the Bax to Bcl2 ratio.

Specific aim 4: To determine if metabolic syndrome increases the susceptibly of myonuclei to
apoptosis during muscle wasting induced by denervation.
Hypothesis 4.1: Mitochondrial associated apoptotic signaling and nuclear apoptosis will
be elevated in denervated skeletal muscles of OZR compared to the LZR.
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BACKGROUND AND SIGNIFICANCE

Clinical significance of metabolic syndrome and obesity.
The results of the National Health and Nutrition Examination Survey 2003-2004 indicate
that an estimated two-thirds of U.S. adults are either overweight or obese, and the prevalence of
obesity is increasing, especially in young people, affecting approximately 17% of Americans 219 years of age (18; 60; 61). With increased obesity there is an elevation of lipids in the
bloodstream, termed lipidemia, which is a major risk factor for the development of metabolic
syndrome and heart disease, the number one cause of death in the U.S. (59). Metabolic syndrome
is defined as a cluster of risk factors for heart disease and type 2 diabetes mellitus including: (i)
obesity, (ii) insulin resistance (with or without glucose intolerance), (iii) hypertension, (iv)
dyslipidemia, (v) a prothrombotic state (e.g., high fibrinogen or plasminogen activator inhibitor–
1 in the blood), and (vi) a proinflammatory state (e.g., elevated C-reactive protein in the blood).
Muscle strength negatively correlates with the development of metabolic syndrome regardless of
age or BMI (39). Moreover, the quality of muscle (strength normalized to cross sectional area) is
significantly reduced in skeletal muscle of persons with obesity and metabolic syndrome (13;
64). Combined, these data indicated that there may be an interaction between obesity and
metabolic syndrome and skeletal muscle regulation.

Importance of skeletal muscle in metabolic syndrome and obesity.
Fasting and postprandial free fatty acid concentrations are elevated in individuals who are
obese or who have metabolic syndrome (31). Thus, insulin target tissues, such as skeletal muscle,
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are constantly exposed to high levels of FFAs. Skeletal muscle is the primary tissue for glucose
and lipid utilization and has become an important target tissue in the study of metabolic
syndrome as it accounts for 55-100% of glucose intolerance (5; 6; 63). Attenuated muscle mass
associated with obesity and metabolic syndrome could be particularly detrimental as blood
glucose and lipid levels increase and the ability to utilize each is diminished. For example, the
obese zucker rat (OZR) is a model of obesity and metabolic syndrome based on chronic
hyperphagia (8), which results in the rapid development of obesity, insulin resistance, and
hyperlipidemia (4; 8; 11; 41). Within the OZR, there is a significant (10-25%) reduction in the
skeletal muscle mass compared to the Lean Zucker rat (LZR) phenotype (25).

Nuclear regulation of muscle mass.
Each myonucleus controls a relatively fixed cytoplasmic area, so growth or hypertrophy
of a muscle fiber is critically dependent on adding new nuclei (1; 34). Muscle satellite cells are
quiescent myogenic precursor cells found between the basal lamina and the sarcolema of a
muscle fiber (34) and they provide the only important means of adding new nuclei to adult
muscle (1; 33; 55; 62; 67). In contrast, apoptosis, or programmed cell death, can selectively
eliminate myonuclei and satellite cells, and can lead to skeletal muscle atrophy (1; 2; 24; 50).

AKT regulation of muscle in obesity and metabolic syndrome.
Protein Kinase B/Akt (Akt) is a family of serine/threonine-specific protein kinases. Two
Akt isoforms are highly expressed in skeletal muscle (Akt1 and Akt2). When Akt is
constitutively activated there is an increase in muscle hypertrophy and a corresponding decrease
in the amount of free fatty acids and adipose tissue (46). On the other hand, when Akt activity is
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reduced there is a corresponding reduction in free fatty acid metabolism and muscle mass (7).
Paradoxically, Akt activity can be inhibited by chronic exposure to certain free fatty acids, such
as palmitate (14; 15), and has been shown to be attenuated with obesity and metabolic syndrome
(16; 43; 45; 75). Additionally, in the OZR, Akt activity is reduced and there is a decreased
nucleic acid content in the skeletal muscles, compared to the LZR (25; 43), further demonstrating
that decreased Akt activity with obesity and metabolic syndrome may be involved with
attenuated skeletal muscle of these animals.

Akt regulation of cell cycle progression and satellite cell proliferation.
Disrupted Akt signaling with obesity and metabolic syndrome may impair satellite cell
proliferation. Akt signaling is integrally involved in the regulation of satellite cell proliferation
and differentiation by controlling cell cycle progression (7; 17; 23; 26; 27; 29; 36; 37; 74; 78;
80). The progression of the cell cycle is as follows: (i) First the cell begins in the G1 phase of the
cell cycle, containing one copy of DNA, (ii) next, DNA replication begins, the S-phase, (iii)
thirdly, the G2 phase in which the cell has two copies of DNA but has not yet divided, (iv) the
final stage of the cell cycle is the M-phase in which the cell begin mitosis, (v) and the cell cycle
is completed with the formation of two new ‘daughter’ cells and begins again in G1 (44). Akt is a
key regulator of cell cycle progression by exerting control at check points G1 and G2 in the cell
cycle.
Akt may control satellite cell progression through cell cycle progression via the cyclindependent kinase inhibitor p21 in (3; 36; 56; 70; 71). As diagramed in figure 1, when in the
nucleus, p21 inhibits cell proliferation, however when phosphorylated by Akt, p21 protein leaves
the nucleus and is no longer able to interfere with cell cycle progression (32; 47; 48; 72).
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Additionally, Akt signaling can enhance proliferation of satellite cells by down-regulating the
negative inhibition of forkhead (FoxO) transcription factor FoxO3a (3; 28; 52).

When

phosphorylated by Akt, FoxO3a leaves the nucleus and removes the inhibition of FoxO3a on
myogenic regulatory factors, like MyoD, and other cell cycle proteins (3; 27; 28; 38; 54). Akt
can also enhance cell cycle progression of satellite cells through regulation of the activity of
cyclin D in the G1-phase and cyclin B1 during the G2/M phase transition (38; 65; 71).
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Figure 1. A schematic representation of Akt action on cell cycle control.
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AKT regulation of satellite cell differentiation.
After proliferation, satellite cells must differentiate and become incorporated into existing
muscle fibers. Satellite cell differentiation is a highly controlled process (49) that is dependent
on the myogenic regulatory factors, MyoD and myognein, and Akt activity. MyoD and
myogenin are muscle-specific helix-loop-helix transcription factors which regulate muscle
specific genes (9; 34; 53; 58). As diagramed in figure 2 it appears that Akt is transcriptionally
regulated by MyoD, and provides a positive feedback to enhance the actions of MyoD to further
increase its own transcription (19; 37; 40). Furthermore, Akt also works in conjunction with
MyoD to promote the transcription of myogenin (40), a necessary step for the progression of
muscle cell differentiation (7). Akt, particularly the Akt2 isoform, is essential for differentiation
to occur. When the expression of Akt2 is inhibited in C2C12 myoblasts, an in vitro model of
muscle satellite cells, there is complete abolishment of differentiation (7; 40). Additionally, Akt
knockout mouse have much smaller muscles than their wildtype counterparts (16; 17), whereas,
over-expression of active Akt induces skeletal muscle hypertrophy (46).
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Figure 2: A schematic representation of Akt action and Myoblast differentiation.
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Akt and myonuclear apoptosis.
Loss of myonuclei via apoptosis is a potential mechanism that could contribute to lower
muscle mass in obesity and metabolic syndrome. As diagramed in figure 3, Akt has been shown
to inhibit apoptosis through a number of pathways (23; 81). Activated Akt inhibits the activity
of the Bcl-associated death promoter (BAD) protein (20). BAD is a proapoptotic member of the
B-cell leukemia/lymphoma-2 (Bcl-2) family that disrupts the binding of Bcl-2 associated X
protein (Bax) from Bcl-2. Once Bax is released from Bcl-2 there is a Bax-Bax-oligomerization,
this Bax-Bax protein complex then inserts into the mitochondrial membrane, causing
mitochondrial permeabilization (82). When the mitochondrial membrane is permeablized there is
a release of proapoptotic factors, such as apoptosis inducing factor (AIF) and cytochrome c,
which begin the apoptotic signaling pathway (10; 42). When released from the mitochondria,
cytochrome c and Apaf-1 activate Caspase-9. Active Caspase-9 activates Caspase-3, an apoptotic
effector that leads to DNA fragmentation and cell death (10; 51). In addition to inhibiting
apoptosis through BAD phosphorylation, Akt also phosphorylates and inhibits the activity of
procaspase-9, thus inhibiting the ability of cytochrome c and Apaf-1 to activate this pathway
(12). It has also been shown in our lab that recently activated satellite cells are more susceptible
to apoptosis, and correlates with changes in Bax and Bcl-2 protein levels (69). Therefore, it
seems reasonable to conclude that there may be increased apoptosis in myoblast or satellite cells
in which the anti-apoptotic effect of Akt will diminish, such as that occurring in obesity and
metabolic syndrome.
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Figure 3: Schematic representation of Akt action on apoptotic signaling.
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OZR as a mode of metabolic syndrome in which to study satellite cell proliferation.
Skeletal muscles of the obese Zucker rat (OZR), a commonly used animal model of
metabolic syndrome, are considerably smaller than the skeletal muscles of the control lean
Zucker rat (LZR) of similar ages (25). The OZR has a homozygous missense mutation of the
leptin receptor gene resulting in chronic hyperphagia (8) and this causes rapid development of
obesity, insulin resistance, and hyperlipidemia as early as 6 weeks of age (4; 8; 11; 41). These
animals also develop hypertriglyceridemia, hypertention, and the genesis of a prothrombotic and
proinflammatory state and therefore, the OZR is considered a good model of metabolicsyndrome
(8; 35). In addition, Akt activity is significantly reduced in the skeletal muscles of the OZR (43),
and defective Akt signaling is a possible mechanism responsible for the attenuated muscle size.
Therefore the OZR provides a good model of metabolic syndrome and obesity in which to
evaluate the potential role of inhibition of satellite cell proliferation resulting in lower muscle
mass. In this project we examined the proliferation of satellite cells in control muscles of the
OZR model of metabolic syndrome and determined if satellite cell activation and proliferation
can be rescued by muscle loading in the OZR. Furthermore, we examined the role of Akt
signaling in control and loaded muscles of the OZR.

Putative role of palmitate in metabolic syndrome and loss of muscle nuclei.
Palmitate is the most abundant systemic saturated fatty acid in muscle and is elevated in
cases of obesity and metabolic syndrome (30; 76) and therefore it has been studied in various
tissues to better understand the effects of saturated fatty acids in dyslipidemia (15; 22; 57; 73;
79). Palmitate treatment has been shown to induce apoptosis in multiple cell types in vitro (21;
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57; 66; 77). Furthermore, palmitate has been found to inhibit Akt/Protein kinase B (Akt) activity
in response to insulin (14; 15; 68). Shorter carbon chained saturated fatty acids, (i.e. laurate), do
not to interfere with Akt signaling (14; 15); however, their impact on apoptosis has not been
examined. In this project we have examined the putative role for palmitate to reduce Akt activity,
leading to apoptosis and loss of nuclei in muscle cells using an in vitro model.
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Palmitate treatment inhibits C2C12 myoblast proliferation and differentiation
Jonathan M. Peterson, Randall W. Bryner, and Stephen E. Alway

ABSTRACT

Myoblast proliferation and differention are highly controlled processes that involve the
coordination of a variety of cell signaling pathways. This progression includes cyclins,
Akt, myogenic regulatory factors, as well as others. The purpose of this study was to
determine whether palmitate interfered with myoblast proliferation and or differentiation.
For these series of experiments C2C12 myoblasts were grown to approximately 60
percent confluence and then treated with or without 0.25 mM palmitate for 12 hours. The
effect of palmitate on myoblast proliferation was determined in two separate experiments
through either pre-staining carboxyfluorescein diacetate, succinimidyl ester (CFSE) or
with post-treatment incubation with 5-bromo-2-deoxyuridine (BrdU).

Both of these

techniques revealed that there was a significant decrease in the rate of proliferation in the
palmitate treated myoblasts. Furthermore, when the cell cycle was analyzed through
Propidium Iodide staining there was a significant accumulation of cells in the G2/M
phase of the cell cycle. Immunoblot analysis of palmitate treated myoblast showed a
significant decrease in p21, Akt2, myoD, and a significant increase in Foxo3a protein
expression. Furthermore, the treatment of myoblasts with palmitate completely abolished
the formation of myotubes.

The absence of myotube formation corresponded with the

attenuation of many of the proteins which are normally rapidly expressed at the onset of
myoblast differentiation, including Akt2, myogenin, and MF20. These data demonstrate
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that palmitate treatment not only inhibits the proliferation of myoblast, but palmitate also
inhibits the formation of new myotubes.
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INTRODUCTION
The transition of mono-nucleated myoblast into fully differentiated multinucleated myotubes is a step-by-step process characterized by cell cycle withdrawal,
expression of muscle-specific proteins, and formation and maturation of myofibers (22).
A large portion of the control process for these process is regulated by the musclespecific helix-loop-helix transcription factors, myoD and myogenin, which are able to
promote the transcription of muscle specific genes (3, 18, 19).

In addition, to the

myogenic regulatory factors, forkhead transcriptions factors and cell cycle proteins also
contribute to the regulation of myoblast differentiation (6, 8).
Recently, it has been demonstrated that Akt1 and Akt2 play distinct roles in cell
cycle progression with Akt1 being required for proliferation while Akt2 promotes cell
cycle exit and is necessary for myoblast differentiation (2, 10, 11). For, example Akt
indirectly, through GSK3-β inhibition, increases the activity of cyclin-D (7, 13). Cyclin D
is a necessary protein for cell cycle progression from the G1 phase of the cell cycle,
whereas in the absence of cyclin D the cell will be unable to progress through the cell
cycle (12, 16).

Additionally, Akt signaling can enhance proliferation through the

forkhead (FoxO) transcription factors. The FoxO family proteins increase the nuclear
expression of negative cell cycle proteins, whereas phosphorylation of the FoxO family
of proteins by Akt negates this effect. Additionally, the inhibition of the FoxO family of
proteins results in their nuclear export thus removing the inhibition of the FoxO proteins
on myogenic regulatory factors (1, 15). On the other hand, it has been postulated that
Akt2 may activate MyoD induced myogenin expression, a necessary step for
differentiation (11). Combining the aforementioned roles of Akt signaling on the FoxO
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family proteins as well as the cell cycle proteins it seems reasonable to assume that
disrupted Akt signaling with metabolic syndrome may not only reduce myoblast/satellite
cell proliferation, but also reduce myoblast/satellite cell differentiation. However, the
effects of metabolic syndrome on muscle cell cycle and differentiation have not been
studied.
The purpose of this study was to determine if the addition of the saturated free
fatty acid (FFA) palmitate inhibits either C2C12 myoblast proliferation and/or
differentiation. Palmitate has been previously demonstrated to inhibit Akt activity in
myotubes but its effects on myoblast proliferation and differentiation are unknown.
Furthermore, a secondary purpose of this study was to investigate some of the specific
signaling that is altered with palmitate treatment that may account for the decreases in
myoblast proliferation and/or differentiation.
METHODS
C2C12 Culture. Mouse C2C12 myoblasts were purchased from American Type Culture
Collection (ATCC).

Cells were cultured in 50 mm polystyrene culture dishes in

Dulbecco Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum, and 1% antibiotic antimycotic mixture. Cells were passaged by trypsinization
using 0.25% trypsin. Cells were maintained in a humidified incubator under an
atmosphere of 5% CO2 at 37 ºC. Fresh medium was supplied every 24-36 hours.
Palmitate (Sigma Chemicals; St. Louis, MO) was administered to cells as
described by Chavez and Summers (4, 5) with dodecanoic acid (Lauric acid) used as a
free fatty acid (FFA) control, with an additional control group receiving media only.
Lauric acid was chosen as a FFA control because it has been shown not to interfere with
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Akt activity (5). However, a BSA only group was also used to determine if the FFAs
affected the measured variables independent of Akt activity. Briefly, palmitate was
dissolved in ethanol and diluted DMEM containing 2% BSA. C2C12 myotubes were
incubated with the FFAs (0.25 mM final concentration) in 10% FBS–DMEM in 2% BSA
for 12 h prior to analysis.

Myoblast proliferation. The first experiment performed was to determine if palmitate
treatment inhibited myoblast proliferation. For this experiment C2C12 myoblasts were
suspended in trypsin, centrifuged at 20ºC for 5 minutes at 1500 rpm and then resuspended
in PBS. Next 10 µM Carboxyfluorescein Diacetate, Succinimidyl Ester (CFSE) was
added to the cells and then the staining was immediately quenched with the addition of an
equal volume of 10% FBS. An aliquot was fixed in 1% paraformaldehyde, to determine
initial staining intensity. The cells were then plated into 35mm plates in 10% FBS and
allowed to grow for 24 hours. At this point the myoblasts were treated with palmitate,
Lauric acid, Akt-inhibitor (124005, Calbiochem, Germany) or BSA only and allowed to
grow for an additional 24 hours. Next, the myoblasts were washed twice with PBS,
harvested in 0.25% trypsin, and fixed with 1% paraformaldehyde, and examined using
the FACSCaliburTM Flow Cytometer.
An additional proliferation assay was performed in a separated experiment in
which the C2C12 myoblasts were grown to ~50 percent confluency, pulsed for 20 min
with 30 µg/ml BrdU (550891, BD Biosciences Pharmingen, USA), harvested in trypsin,
and fixed in ice cold 70% EOTH for 24 hours. The myoblast were then resuspended in
0.1% triton-X/0.1 M HCL for 1 min, centrifuged at 2000 rpm for 5 min, then resuspended
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in DNA Denaturing Buffer (0.15 µM NaCl, 15 µM Trissodium citrate dihydrate) at 95°C
for 5 min, followed by incubation at 4ºC for 5 min, and centrifuged 2000 rpm 5 min.
Next the pellet was washed in 1% BSA in PBS and then resuspended in Mouse anti-BrdU
(1:50; 555627; BD Pharmingen™, USA) for 30 min at room temperature. The cells were
then washed twice in PBS and incubated with Anti-mouse Alexa-488 secondary antibody
(1:400; A11029; Invitrogen, USA). Lastly, the myoblasts were wash twice with PBS and
then resuspended in Propidium Iodide (10 µg/ml; P3566, Invitrogen, USA), RNAse (100
µg/ml; 10109169001; Roche, USA) in PBS and analyzed using the FACSCaliburTM Flow
Cytometer.

Flow Cytometry Analysis. The samples were transferred to 5 ml polstytrene round
bottom tubes for data acquisition and analysis on a FACSCaliburTM Flow Cytometer
using CellQuest Pro software (BD Biosciences).

All data are represented as mean

fluorescence intensity (MFI). Additional cell cycle modeling was performed using Modfit
LT software (Verity Software house, Inc).

Myoblast differentiation. For differentiation into myotubes, the myoblasts were
grown to 70% confluency and then treated for 12 hours with FFAs (0.25 mM final
concentration) or BSA only for 12 hours. After treatment the cells were washed three
times with DHANKs and then transferred to DMEM containing ITS liquid media
(Sigma-Aldrich, St. Louis, MO). All experiments were performed in triplicate.
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Immunoblot analysis. The protein contents of the solublized extracts were quantified in
duplicate by using bicinchoninic acid reagents (Pierce, Rockford, IL, USA) and bovine
serum albumin (BSA) standards. 60 µg of soluble protein was boiled for 4 min at 100°C
in Laemmli buffer and loaded on each lane of a 12% polyacrylamide gel. The proteins
were separated by routine SDS-PAGE for 1.5 hours at 20°C. The gels were blotted to
nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) and stained with Ponceau S red
(Sigma Chemical Co, St Louis, MO, USA) to confirm equal loading and transferring of
proteins to the membrane in each lane.
The membranes were then blocked in 5% non-fat milk in Tris buffered saline with
0.05% Tween 20 (TBS-T) and probed with appropriate primary antibodies (see table 1).
Secondary antibodies were conjugated to horseradish peroxidase (HRP) (Chemicon, CA,
USA) and the signals were developed by chemiluminescence (Pierce, Rockford, IL,
USA). The signals were visualized by exposing the membranes to X-ray films (BioMax
MS-1, Eastman Kodak, Rochester, NY, USA), and digital records of the films were
captured with a Kodak 290 camera. The resulting bands were quantified as optical
density (OD) x band area by a one-dimensional (1-D) image analysis system (Eastman
Kodak, Rochester, NY, USA) and expressed in arbitrary units. The sizes of the proteins
were verified by using standard molecular-weight markers (Bio-Rad, Hercules, CA,
USA). To reduce the day-to-day variability between blots all comparisons were
performed on samples run on the same membrane.

Statistical analyses. Statistical analyses were performed using the SPSS 10.0
software package. A one-way ANOVA was performed on the difference between each
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variable among treatments. Statistical significance was accepted at P < 0.05. All data are
given as means + SE.

RESULTS

Myoblast proliferation. The first part of this study design was to determine if palmitate
treatment attenuated myoblast proliferation. CFSE is a fluorescent dye that stains all the
protein in the cell. A subset of the cells was preserved as the parent generation (figure
1A), each time the myoblast divide the intensity of the stain is reduced by approximately
one-half. The myoblast were obtained from one set of parent cells and allowed to grow
for 24 hours under control treatment. Our pilot data demonstrated that after 24 hours the
myoblasts divided approximately three times in the first 24 hours (Data not shown).
After 24 hours of control treatment the myoblasts were incubated with FFAs, BSA only
control, or Akt-inhibitor for an additional 24 hours (48 hours total). The proliferation
index is an estimation of the number of times the myoblast divided based on the change
of CFSE fluorescence intensity of the treated myoblasts compared to the parent
generation (Sample histograms are shown figure 1A and 1B). This experiment showed
that both palmitate and the Akt-inhibitor both significantly reduced myoblast
proliferation (Figure 1C).
BrdU is incorporated into proliferating myoblasts as they transition through the Sphase of the cell cycle. Figure 2 shows that with both palmitate treatment and Akt
Inhibitor significantly reduced the incorporation of BrdU into the myoblasts. Combining
the CFSE data and the BrdU data it is clear that palmitate treatment significantly reduces
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Furthermore, when the cell cycle was analyzed through

examination of the PI staining it clearly demonstrated that there was a G2 cell cycle shift
in the palmitate treated myoblasts (figure 3). This was different then the Akt inhibitor
treated myoblast which had an increase accumulation in both G1 and G2 cell cycle
phases. It has been previously demonstrated that Akt activity is involved with both the
G1 and G2 cell cycle check points (8, 9, 14), however it is unclear why there is a G2 cell
cycle shift in the palmitate treated myoblasts.

Akt protein Expression.

To determine the putative impact of Akt signaling in

accounting for the decrease proliferation in palmitate treated myoblasts the protein
expression of Akt was determined. After palmitate treatment there was no change in the
protein expression of total Akt or Akt1. However, there was a significant absence of
Akt2 protein expression in palmitate treated myoblasts (Figure 4A). It should be noted
that in C2C12 myoblasts the protein expression of Akt2 is extremely small compared to
the expression of Akt1 isoform.

In this study the exposure time for Akt1 was

approximately 30 seconds compared to 5 minutes for Akt2 with all steps besides primary
antibody being equal. This would explain why there is no difference observed in either
total Akt or Akt1 protein expression even though Akt2 protein expression is significantly
reduced.
To determine whether Akt activity was reduced with the palmitate treatment the
myoblasts were treated as above, and then incubated in serum free media (with or without
FFAs) for 2 hours before serum was reintroduced to the samples for 10 minutes before
harvest. There was a significant reduction in pAkt (Serine 473) protein expression after
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the reintroduction of serum in the palmitate treated myoblasts (Figure 4B). This indicates
that although palmitate did not alter total Akt protein expression it did attenuate the Akt
activity, as determined through decreased protein expression of pAkt.

Cell cycle regulatory proteins. To further evaluate the mechanism for palmitate induced
G2 cell cycle phase shift the expression levels of other G2 regulatory proteins were
investigated. The protein expression of the myogenic regulatory factor MyoD and the
cyclin-dependent kinase inhibitor p21 were both reduced in the palmitate treatment
myoblasts. On the other hand there was an approximately 2-fold increase in the protein
expression of forkhead transcription factor Foxo3A (figure 5A).

These data are

consistent with the previous finding of a G2 cell cycle shift and may be part of
mechanism accounting for the G2 shift. Other proteins that were examined include p27,
p53, Foxo1, and Foxo4 however, no differences were observed in the protein expression
of these proteins with palmitate treatment (data not shown). On the other hand, a small
decrease in the protein expression of the cell cycle regulatory protein Cyclin B1 with
palmitate treatment was observed. However, a band was also observed at ~60 kDa which
corresponds with a hyper-phosphorylated form of Cyclin B1 in both control treatments,
but was absent in the palmitate treated myoblasts (figure 5B). Furthermore, when either
the BSA or Lauric acid control groups were treated with an Akt inhibitor the 60 kDa band
of Cyclin B1 was no longer present.

Differentiation. The last part of this study was to determine whether palmitate treatment
interfered with the ability for the myoblast to differentiate. For this series of experiments
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the myoblasts were treated for 12 hours with or without the FFAs and then washed and
transferred to differentiation media. The myoblasts were trypsin harvested at 6, 12, and
24 hours after being the start of differentiation and stained for Annexin V. Annexin V is
an early marker for cells that are undergoing apoptosis, as there is a translocation of the
membrane phosphatidylserine (PS) from the inner face of the plasma membrane to the
cell surface, or have become necrotic and the membrane integrity is diminished.
Although there was no increase in Annexin V positive myoblasts in the palmitate pretreated myoblasts after 6 hours in differentiation media, there was an approximately 2fold increase in the percent of cells that were Annexin V positive at both 12 and 24 hours
after the initiation of differentiation.
Furthermore, cells were harvested 48 hours after the beginning of differentiation
and the expression of proteins that are expressed during differentiation were examined.
The data clearly demonstrates the absence of the proteins that are normally expressed
during differentiation (figure 6B). Combined these data demonstrate that the treatment
on myoblast with palmitate attenuates myotube formation.
Discussion
The novel findings of this study are that palmitate treatment significantly reduces
myoblast proliferation and differentiation. Furthermore, these data demonstrated that
with palmitate treatment there is a significant G2 cell cycle shift, indicating that with
palmitate treatment the myoblasts are unable to pass the G2-check point (17, 21).
Although palmitate treatment resulted in a reduction in pAkt protein expression and this
may partially account for the decreased proliferation, and the Akt inhibitor also decreased
proliferation, the reduction in pAkt protein expression is not sufficient to explain the G2
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cell cycle shift. The G2 cell cycle shift may be explained by some of the other proteins
whose expression levels were alter with the palmitate treatment. There was a significant
reduction in protein expression of p21 and MyoD and an increase in the protein
expression of Foxo3A. Additionally, there was a significant attenuation of a hyperphosphorylated Cyclin B1, with palmitate and with Akt inhibitor. Combined these data
shed light on a possible mechanism for the G2 cell cycle shift in the palmitate treated
myotubes (8, 17, 20, 21).
On the other hand the absence of Akt2 in palmitate treated myoblast most likely
does not contribute to the attenuated proliferation, but may be a mechanism responsible
for the attenuation of myoblast differentiation (2, 10, 11). It has been previously shown
that when Akt2 is reduced with siRNA treatment in C2C12 myoblast there is complete
abolishment of myotube formation, whereas Akt1 siRNA transfection had no effect on
differentiation (2). It has been proposed that myoD and Akt2 work in conjunction to
induce the expression of myogenin, a necessary step for myotube formation to occur.
Combined these data demonstrate that palmitate treatment of C2C12 myoblast
significantly attenuates proliferation and abolishes myotube formation.
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FIGURE LEGENDS

Figure 1. CFSE is a fluorescent dye that stains all the protein in the cell. After initial
treatment with CFSE dye a subset of the cells was preserved as the parent generation, a
histogram with the mean fluorescent intensity in a log scale on the x-axes and cell count
on the why axis is shown (A). After 24 hours of control treatment the myoblasts were
incubated with FFAs, BSA only control, or Akt-inhibitor for an additional 24 hours
before trypsin harvest. Representative histogram of control myoblasts grown in 10%
FBS for 48 hours after initial CFSE treatment is shown (B). Each time the myoblast
divide the intensity of the stain is reduced by approximately one-half. The proliferation
index is an estimation of the number of times the myoblast divided based on the change
of CFSE fluorescence intensity of the treated myoblasts compared to the parent
generation (C). This experiment showed that both palmitate and 10 µM Akt-inhibitor
both significantly reduced myoblast proliferation. The data are displayed as mean ± SE.
*p < 0.05 vs. control samples. Abbreviation: Con = BSA only control; Laur = Lauric
acid free fatty acid control; Pal = Palmitic acid treated AktI = Treated with 10 µM Akt
Inhibitor; CFSE = Carboxyfluorescein Diacetate, Succinimidyl Ester.

Figure 2. BrdU is incorporated into proliferating myoblasts as they transition through
the S-phase of the cell cycle. Figure 2A shows a representative graph displaying Flow
Cytometry data with the mean fluorescent intensity (MFI) of BrdU-alexa 488 on the yaxis and MFI of propidium Iodide on the x-axis. Figure 2B displays the number of cells
for each treatment that are BrdU positive. The data are displayed as mean ± SE. *p <
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0.05 vs. control samples. Abbreviations: Con = BSA only control; Laur = Lauric acid
free fatty acid control; Pal = Palmitic acid treated; AktI = Treated with 10 µM Akt
Inhibitor; BrdU = Bromodeoxyuridine (5-bromo-2-deoxyuridine).

Figure 3. Cell cycle was analyzed through examination of the PI staining. A)
Representative histogram is demonstrated cell number in is each phase of the cell cycle
based on the staining intensity of Propidium Iodide. B) Palmitate and AktI treated
myoblasts had significantly decreased number of myoblasts in the S-phase of cell cycle.
Palmitate treatment resulted in a significant accumulation of myoblasts in the G2/M
phase of the cell cycle. The data are displayed as mean ± SE. *p < 0.05 vs. control
samples. Abbreviations: Con = BSA only control; Laur = Lauric acid free fatty acid
control; Pal = Palmitic acid treated; AktI = Treated with 10 µM Akt Inhibitor.
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ABSTRACT
The obese Zucker rat (OZR) is a model of the metabolic syndrome, which has lower skeletal
muscle size compared to the lean Zucker rat (LZR).

Because satellite cells are essential for

postnatal muscle growth, this study was designed to determine if reduced satellite cell
proliferation contributes to the reduction of skeletal mass in the OZR compared with the LZR.
Satellite cell proliferation was determined by a constant release 5-bromo-2-deoxyuridine (BrdU)
pellet that was placed subcutaneously in each animal. Satellite cell proliferation, as determined
by incorporation of BrdU, was significantly attenuated in control soleus and plantaris muscles of
the OZR compared to the LZR. To determine whether this attenuation of satellite cell activity
could be rescued in OZR muscles, the soleus and the gastrocnemius muscles were denervated,
placing a compensatory load on the plantaris muscle. There was a ~25% and ~30% increase in
the plantaris muscle wet weight compared to the contra-lateral control muscle in the LZR and
the OZR, respectively after 21-days of loading. The number of BrdU positive nuclei increased
similarly in loaded plantaris muscles from LZR and OZR. Myogenin, MyoD and Akt protein
expression, were lower in the control muscles of OZR compared to LZR, but they were all
elevated to similar levels in the loaded plantaris muscles of OZR and LZR. These data indicate
that metabolic syndrome may reduce satellite cell proliferation and this may be a factor that
contributes to the reduced mass in control muscles of OZR; however, satellite cell proliferation
can be restored with compensatory loading in OZR.

Key Words: muscle stem cells, muscle hypertrophy, metabolic syndrome, myogenic
transcription factors
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Introduction
The obese Zucker rat (OZR) is a widely accepted model of the metabolic syndrome, which
occurs as a result of a homozygous missense mutation of the leptin receptor gene (9) leading to
chronic hyperphagia (9,21). As a result, the OZR rapidly becomes obese and develops extreme
insulin resistance and hypertriglyceridemia, which is accompanied by a clinically relevant
hypertension and a prothrombotic and proinflammatory state (5,16,20,22,28,36). Skeletal
muscles are considerably smaller in the OZR than in the control lean Zucker rat (LZR) of similar
ages. This is important because skeletal muscle, is the primary site of glucose and fat oxidation,
both of which are in excess with metabolic syndrome (6,27). Therefore, a reduction of skeletal
muscle mass would further compromise clinical outcomes in metabolic syndrome.
The lower skeletal muscle mass in the OZR appears to be partly accounted for by an altered
balance between protein synthesis and degradation in this model of metabolic syndrome (4,16).
However, it has also been observed that there is a decrease in nucleic acid content in the muscles
of the OZR compared to the LZR (16). Replacing nuclei that are lost during normal turnover and
maintaining nuclear content in adult muscle, is a primary responsibility of muscle satellite cells.
Muscle satellite cells are normally quiescent myogenic precursor cells found between the basal
lamina and the sarcolemma of a muscle fiber (1). However, these cells can proliferate in
response to a variety of stimuli, and they are responsible for maintenance of the nuclear to
cytoplasmic relationship in muscle. Furthermore, postnatal muscle growth and hypertrophy of
skeletal muscle, critically depend on the proliferation and differentiation of muscle satellite cells
(1,25). It is possible that a decrease in satellite cell proliferation could contribute to the decrease
in nucleic acid content and skeletal muscle mass observed in the OZR.
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Mechanisms that may contribute to lower satellite cell proliferation and differentiation in
muscles of the OZR could include decreases in the expression levels of myogenic regulatory
factor proteins. Myogenic regulatory factors are muscle-specific helix-loop-helix transcription
factors which regulate muscle specific genes (12,25).

MyoD and myogenin are myogenic

regulatory factors which are expressed in activated satellite cells and they are necessary for
satellite cell proliferation and differentiation (12,37). MyoD and myogenin are reduced during
muscle atrophy, and in models of diabetes (3,13), although it has not been determined if this
corresponds to reduced satellite cell proliferation or differentiation in models of the metabolic
syndrome. We hypothesized that a decrease in the protein expression of MyoD and myogenin
might result in lower satellite cell proliferation and/or differentiation and lead to lower muscle
mass in the OZR model of metabolic syndrome, as compared to the lean phenotype.
Another possible mechanism for disrupted satellite cell proliferation is deregulated protein
kinase B/Akt (Akt) signaling. Control of the Akt signaling pathway is essential for muscle
growth and hypertrophy (reviewed (7,19)). Furthermore, a lower level of activated Akt is
associated with attenuated increases in muscle hypertrophy under conditions such as aging
(7,19). Akt, and specifically Akt2, is essential for proliferation and differentiation of skeletal
muscle satellite cells (7,8). In the OZR there is a reduced protein expression of Akt2 and
reduced activity levels of both Akt1 and Akt2 compared to the LZR (24). These findings
underscore the possibility that Akt signaling may play an important role in the control of satellite
cell proliferation and differentiation in muscles of the OZR.
Although the skeletal muscles of the OZR are smaller compared to the LZR, to the best of
our knowledge, no study has evaluated whether muscles in the OZR have attenuated hypertrophy
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in response to loading. While the OZR is significantly less active than the LZR (9), the OZR
have much greater body mass, and this should provide a greater stimulus for muscle growth on
the weight bearing muscles. Nevertheless, a previous study from our lab in which the daily
activity of the OZR was increased through daily treadmill running, demonstrated no increase in
the size of the skeletal muscles (18). These findings suggest that there may be an underlying
deficit in the ability of skeletal muscle to respond to increased loading in the OZR model of
metabolic syndrome.
The purposes of this study were to determine (i) if there was a decrease in the number of
satellite cells in the skeletal muscles of the OZR compared to the LZR (ii) whether satellite cell
proliferation is attenuated in OZR compared to the LZR in control muscle; (iii) whether satellite
cell proliferation is attenuated in OZR compared to the LZR in loaded muscle; and, (iv) whether
the skeletal muscles of the OZR are able to hypertrophy in response to loading. Furthermore, as
muscle loading directly activates Akt (31) and MRF signaling (2,26), Akt, MyoD, and myogenin
protein expression were measured. We hypothesized that Akt and MRF protein expression would
be rescued with compensatory hypertrophy in the OZR, and enable a restoration of satellite cell
proliferation to levels similar to lean animals.
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METHODS
Animal Care. Male LZR (+/fa) and OZR (fa/fa) rats were purchased from Harlan labs
(Harlan, Indianapolis, IN). The OZR are homozygous for a recessive missense mutation of the
leptin receptor gene which results chronic hyperphagia. The LZR are heterozygous for this
mutation but do not shown eating abnormalities (9,29). Twelve animals of each phenotype were
used in this study. All animals were 12 weeks of age at completion of this study. The animals
were housed in pathogen-free conditions, at 20-22°C, and fed rat chow and water ad libitum
throughout the study period. The animal care standards were followed by adhering to the
recommendations for the care of laboratory animals, as advocated by the American Association
for Accreditation of Laboratory Animal Care, which fully conformed to the Animal Welfare Act
of the US Department of Health and Human Services. All animal procedures were conducted in
accordance with institutional guidelines and ethical approval was obtained from the Animal Care
and Use Committee at the West Virginia University prior to carrying out tests.
Compensatory loading protocol. To achieve compensatory hypertrophy of the plantaris
muscle, synergist denervation of the soleus and gastrocnemius muscles was used as previously
described in our (14). Briefly, the distal branches of the tibial nerve were transected, therefore,
removing the innervation to the soleus muscle and both heads of the gastrocnemius muscle. The
severed nerved endings were sutured onto the biceps femoris muscle to prevent reinnervation
back to the original muscles (14). This placed a compensatory load on the plantaris muscle. The
contralateral limb received a sham surgery, in which the branches of the tibial nerve were
identified but not severed, and this served as an internal control for each animal. All procedures
were performed under aseptic conditions. The animals recovered quickly and were alert and
walking within ~15 min after surgery. Loading occurred for 7 or 21 days.
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Bromodeoxyuridine (BrdU) implantation. A time-released 5-bromo-2-deoxyuridine (BrdU)
pellet (21-day release, 0.22 µg BrdU·g body mass–1·day–1; Innovative Research, Sarasota, FL)
was placed subcutaneously on the dorsum of the back of each animal. BrdU is a thymidine
analog and is incorporated in nuclei during DNA synthesis. Skeletal muscle nuclei are postmitotic and cannot incorporate BrdU into their DNA. In contrast, satellite cells can incorporate
BrdU during proliferation. Therefore, BrdU positive nuclei located under the basal lamina can
be identified as satellite cells that have proliferated, migrated and become incorporated into a
muscle fiber (1). Therefore, BrdU was used to identify satellite cells/muscle precursor cells that
had proliferated during the 7- or 21-day period of muscle loading-induced hypertrophy. Only the
BrdU positive nuclei within the basal lamina were quantified. The BrdU labeling index was
calculated as the number of BrdU labeled myonuclei . total myonuclei-1 . 100. This provided an
index of satellite cell proliferation.
Tissue Collection. The plantaris muscles were collected 7 days (n=6 LZR-7 and n=6
OZR-7) or 21 days (n=6 LZR-21 and n=6 OZR-21) after the surgical denervation of the
synergists. The animals were 12 weeks old at time of tissue collection. The rats were
anaesthetized with ketamine hydrochloride, (9 mg x 100 g body weight–1) and xylazine
hydrochloride (1 mg x 100 g body weight–1), I.P. and the plantaris muscles from each limb were
removed and frozen in isopentane, cooled to the temperature of liquid nitrogen, and stored at 80°C until further analysis. Additionally, a mid-belly section of each muscle was fixed in 10%
formalin and was embedded in paraffin.
Immunoblot protein analysis. Total protein homogenates were prepared in lysis buffer
(20 mM Tris pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% Sodium Deoxycholate, 1 mM
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EDTA, 0.1% SDS) with the addition of a protease inhibitor (Sigma Chemical Co, St Louis, MO,
USA). The protein contents of muscle homogenates were quantified in duplicate by using
bicinchoninic acid reagents (Pierce, Rockford, IL, USA) and bovine serum albumin (BSA)
standards. The mitochondria-free cytosolic protein fraction was isolated as previously described
(33) and used for immunoblotting for apoptosis inducing factor (AIF). AIF was used as an index
of mitochondria permeability and release of pro-apoptotic factors to the cytosolic protein
fraction. 50 µg of soluble protein was boiled for 4 min at 100°C in Laemmli buffer and separated
on a 4-12% gradient polyacrylamide gel (Invitrogen, USA).

The gels were blotted to

nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) and stained with Ponceau red (Sigma
Chemical Co, St Louis, MO, USA) to confirm equal loading and transfer of proteins to the
membrane.
The membranes were then blocked in 5% non-fat milk in Tris buffered saline containing
0.05% Tween 20 (TBS-T) and probed with antibodies to Akt, Akt1, Akt2 (Cell Signaling
Technology, MA, USA), MyoD or myogenin (Santa Cruz, CA, USA). To determine if apoptotic
signaling was enhanced in control muscles of OZR animals, the membranes were probed with
antibodies to: AIF, apoptotic protease activating factor 1 (Apaf-1), apoptosis repressor with a
caspase recruitment domain (ARC), and Bcl-xL/Bcl-2 associated death promoter (BAD), (Santa
Cruz, CA, USA). As a further confirmation of equal loading and blotting of the proteins, the
membranes were also probed for ß-tubulin or GapDH (Abcam, MA, USA). Secondary antibodies
were conjugated to horseradish peroxidase (Chemicon, CA, USA) and the signals were
developed by chemiluminescence (ECL advance, Amersham Biosciences).

The signals were

visualized by exposing the membranes to X-ray films (BioMax MS-1, Eastman Kodak,
Rochester, NY, USA), and digital records of the films were captured with a Kodak 290 camera.
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The resulting bands were quantified as optical density (OD) x band area by a one-dimensional
(1-D) image analysis system (Eastman Kodak, Rochester, NY, USA) and expressed in arbitrary
units normalized to ß-tubulin or glyceraldehyde 3-phosphate dehydrogenase (GapDH; Abcam
Inc. Cambridge, MA).

Immunofluorescent staining. Paraffin embedded, 7-µm-thick, muscle-cross sections from
loaded and control plantaris muscles were de-paraffinized in xylene, followed by rehydration in
graded ethanol washes, and then rinsed in distilled water. The tissues sections were incubated in
an antigen retrieval buffer (10mM sodium citrate, 0.05% Tween-20, pH 6.0) for 30 minutes at
95ºC, washed in phosphate buffered saline (PBS) and then blocked in 1.5% goat serum in PBS at
37ºC for 30 min. Sections were then incubated with an anti-BrdU mouse monoclonal antibody
(BD Pharmingen, San Diego, CA) followed by an anti-mouse Alexa 488 (Invitrogen, CA).
Negative control experiments were done by omitting the BrdU antibody from the tissue sections.
The basal lamina was identified with a primary antibody to anti-laminin (D18; Hybridoma Bank)
followed by a rhodamine conjugated secondary antibody (Santa Cruz Biotechnology, CA). Only
the BrdU positive nuclei within the basal lamina were quantified. The BrdU labeling index was
calculated as the number of BrdU labeled nuclei. total nuclei

-1 .

100. This provided an index of

satellite cell proliferation.
Pax7 antibody (PAX7; Developmental Studies, Hybridoma Bank, U. Iowa) was used to
determine the number of satellite cells in the control muscles (40). Since the formalin fixation
interfered with the Pax7 antibody, 7µm cross-sections were obtained from frozen mid-belly
sections of the muscle as previously performed in our laboratory (34). Briefly, the sections were
air dried at room temperature, fixed in ice-cold methanol-acetone (1:1) for 10 minutes, rinsed in
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PBS, and permeabilized in 0.2% triton-X in 0.1% sodium citrate. The sections were incubated
for 30 minutes in 1.5% goat serum at 37ºC then incubated with a primary antibody to Pax7
followed by Alexa 488. The tissue sections were then probed with anti-Laminin mouse IgG2a
(2E8; Hybridoma Bank) followed by a rhodamine conjugated secondary antibody (Santa Cruz
Biotechnology, CA).
Immunoblot analysis was completed on 6 non-overlapping tissue cross-sections (40x
magnification). Three cross- sections were examined in each muscle. Myonuclei were only
counted for analysis if they resided within the basal lamina. Pax7 positive nuclei were identified
as quiescent satellite cells, because neither myonuclei nor activated/differentiated satellite cells
express Pax7 (40). Additionally, skeletal muscle nuclei are post-mitotic, and therefore any
nuclei residing under the basal lamina that were BrdU positive were identified as proliferated
satellite cells (1). The BrdU labeling index was calculated as the number of BrdU labeled
myonuclei . total myonuclei-1 . 100 and this was used as an index of satellite cell proliferation.

In situ TdT-mediated dUTP nick end labeling (TUNEL) staining. Apoptotic nuclei were
assessed from muscle cross-sections via a TUNEL assay. 10-μm-thick frozen sections were cut
in a freezing cryostat at -20°C from plantaris muscle cross-sections. Apoptotic nuclei were
identified by a fluorometric TUNEL detection kit (Roche Applied Science, Indianapolis, IN)
according to the manufacturer’s instructions for both C2C12 myoblasts and muscle cross
sections. Briefly, tissue sections were fixed in 4% paraformaldehyde in PBS, pH 7.4, at room
temperature for 20 min, permeabilized with 0.2% Triton X-100 in 0.1% sodium citrate at 4°C for
2 min, and incubated with fluorescein-conjugated TUNEL reaction. Negative control
experiments were done by omitting the TdT enzyme in the TUNEL reaction mixture on the
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tissue sections. After TUNEL labeling, the muscle sections were incubated with an anti-laminin
monoclonal antibody (2E8; Hybridoma Bank, Iowa) followed by an anti-mouse (Cy3 Conjugate,
C2181) and mounted with 4',6-Diamidino-2-phenylindole (DAPI; Vectashield® mounting
medium). TUNEL- and DAPI-positive nuclei and laminin staining were examined under a
fluorescence microscope, and the captured images were stacked using a SPOT RT camera
(Diagnostic Instruments, Sterling Heights, MI), and SPOT RT software (Universal Imaging,
Downingtown, PA). The number of TUNEL and DAPI-positive nuclei was counted from six
random, non-overlapping fields at an objective magnification of x40. Only the labeled nuclei that
were under the laminin staining were counted, to exclude any non-muscle nuclei in the sections.
Data were expressed as number of TUNEL-positive nuclei per 100 nuclei counted.

Statistical analyses. Statistical analyses were performed using the SYSTAT 11.0 software
package. A one way Analysis of variance (ANOVA) was performed on the difference in all
measured variables. The effect of loading on muscle wet-weight was determined by comparing
muscle wet-weights from control and loaded limbs with a paired T-test. The percent change in
muscle wet weight was calculated for each individual animal and the means from these data for
each animal group (n=6/group) are presented in Figure 1. Satellite cell proliferation index, body
weight, control or loaded soleus muscle weight, control or loaded plantaris muscle weight, Pax7
positive nuclei, BrdU positive nuclei, protein expression levels, and nuclei number per muscle
fiber were analyzed using a 2 way ANOVA (phenotype x treatment; control or loaded).The
satellite cell proliferation index, and protein expression were not compared between 7 days post
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surgery and 21 days post surgery. Statistical significance was accepted at P < 0.05. All data are
presented as means + standard error.
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RESULTS
Muscle characteristics. The OZR had significantly more body weight than the LZR. The
control plantaris and soleus muscles of the OZR were significantly smaller than the LZR after 7or 21 days of compensatory loading. 7-days of loading did not significantly increase muscle wet
weight in either LZR or OZR. However, 21 days of loading increased the mass of the plantaris
muscles by 23 + 12.8% in the LZR-21 and 32 + 13% in the OZR-21 (Figure 1). These data
indicate that the compensatory loading protocol used in this study was sufficient to induce
hypertrophy in both the obese and lean phenotype over a 21-day time point.
Quiescent satellite cells. Pax 7 was used as a marker to identify quiescent satellite cells
(40) in tissue cross-sections from soleus and plantaris muscles. The number of quiescent satellite
cells was expressed as a percentage of total myonuclei (DAPI-positive nuclei within the muscle
fiber, as determined by staining of the basal lamina). The percentage of Pax7 positive nuclei to
total myonuclei was similar in plantaris and soleus muscles of OZR and LZR animals (Figure
2A). However, there were fewer total myonuclei in muscles of OZR animals compared to LZR
animals. There was a significant, ~30% and 20% decrease, in the number of myonuclei per
muscle fiber cross section in plantaris and soleus muscles respectively, of OZR compared to the
LZR (Figure 2B). Together these data signify that although the percentage of satellite cells (as
indicated by Pax7) to total myonuclei is not reduced, there are less total myonuclei in the OZR.
This suggests that there was not a preferential loss of satellite cells in the muscles of the OZR,
but rather, there was a proportional decrease in the number of satellite cells and myonuclei in
muscles of OZR compared to LZR.
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Apoptotic signaling proteins. We examined if increased nuclear apoptosis may account
for the fewer nuclei found in muscles fibers of the OZR compared with the LZR. Surprisingly,
immunoblot analysis showed similar levels of AIF, ARC, APAF-1, and Bad protein content in
control muscles of OZR and LZR (Figure 3). Similarly, apoptotic nuclei as reflected by the
frequency of TUNEL positive nuclei were less than 1% of the total myonuclei and there was no
difference in the number of apoptotic nuclei in the muscle cross-sections from LZR and OZR
animals. These data suggest that apoptosis is not increased and therefore cannot account for the
fewer number of myonuclei and satellite cells in muscles of the OZR compared with the LZR.

Satellite cell proliferation. One possible explanation for the lower number of myonuclei
is that satellite cell proliferation and replacement of nuclei could be impaired in control muscles.
To test this possibility, we examined satellite cell proliferation in the muscles of the OZR
compared to the LZR, in control muscles. To determine if satellite cell proliferation could be
rescued to contribute to muscle hypertrophy, we examined loaded plantaris muscles. BrdU time
release pellets were implanted in all animals to label proliferated satellite cells. In the
contralateral control limb there was a significant absence of BrdU positive nuclei in the OZR
compared to the LZR in both the plantaris (Figure 4D) and soleus muscles (Figure 4E). In this
study, only one BrdU positive myonuclei was observed in all the control plantaris muscle cross
sections that were examined from OZR, and only two BrdU positive myonuclei were observed in
all of the control OZR soleus muscles. In contrast, every cross section that was examined in the
LZR had a minimum of one BrdU positive nuclei. These data support the hypothesis that there is
a decrease in satellite cell proliferation in the control muscles of the OZR compared to the LZR.
On the other hand, loading of the plantaris muscle induced a significant increase in the number
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of BrdU positive muscle nuclei in both the OZR and LZR (Figure 4D). The number of BrdU
positive nuclei was similar in loaded muscles from OZR animals.
Myogenic regulatory factors and Akt protein expression. As expected, immunoblot
analysis demonstrated that there was a significant decrease in both MyoD and myogenin protein
levels in the control plantaris muscles of the OZR compared to the LZR (Figure 5). After 7-days
of loading there was a similar ~2 and ~3-fold increase in the relative protein level of myogenin
and MyoD, respectively, in both the LZR and OZR. After 21-days of loading, there was no
longer a difference in the protein expression of MyoD and myogenin in the loaded plantaris
muscles of LZR compared to the control limbs. However, MyoD and myogenin protein levels
remained elevated in the plantaris muscles from OZR after 21-days of loading compared to the
contralateral control (Figure 5).
There was a decrease in total Akt protein expression as well as the relative Akt2 isoform
content, with no changes in Akt1 content in the control muscles of the OZR compare to the LZR.
Compensatory loading increased the protein expression of both Akt1 and Akt2 protein content in
plantaris muscles of the LZR and the OZR (Figure 6). After 21-days of loading, there was no
difference in total Akt, Akt1, or Akt2 protein expression in the loaded plantaris muscle of the
OZR compared to the LZR. These data indicated that although the protein expression levels of
myogenic regulatory factors and Akt are reduced in control muscles in the OZR model of
metabolic syndrome, they can be restored with a sufficient stimulus such that induced during
compensatory loading.
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DISCUSSION
This study demonstrated a number of novel findings regarding satellite cell proliferation
in the skeletal muscles of the OZR model of metabolic syndrome. First, there was a decrease in
the number of myonuclei in muscle fiber cross-sections of the OZR compared with the LZR.
Second, this study is the first to show that hypertrophy is not impaired in muscles of the OZR
model of metabolic syndrome, if the stimulus is adequate. In addition, to the best of our
knowledge, this is the first study to observe any form of loading-induced hypertrophy in any
rodent model of metabolic syndrome. The third novel finding is that although there is no change
in the proportion of quiescent satellite cells in control muscles, there was a significant
attenuation of satellite cell proliferation of adult muscle under normal control loading conditions
in the OZR compared with the LZR. The attenuation of satellite cell proliferation in control
soleus and plantaris muscles that we observed in this study, may result in a decreased
replacement of myonuclei during normal nuclear turnover. This could account for the decreased
nucleic acid content in the skeletal muscles of the OZR compared to LZR observed by Durschlag
and colleagues (16), as well as the decreased number of myonuclei in muscle fiber cross-sections
in the OZR compared to the LZR. It has been previously shown that both Akt protein expression
and activity levels are decreased in control muscles of the OZR when compared with the LZR
(24). Because Akt signaling is a major component contributing to skeletal muscle hypertrophy
(7,11), it was anticipated that the lower Akt protein levels in plantaris muscles of the OZR
would result in attenuated hypertrophy in response to compensatory loading compared to the
LZR. However, no attenuation of satellite cell proliferation or muscle hypertrophy was found in
the OZR after compensatory loading of the plantaris muscle.
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Muscle hypertrophy in response to normal growth or muscle loading in adults is critically
dependent on the proliferation and differentiation of satellite cells (30). Reduction in muscle
DNA content (10) as a result of reduced muscle nuclei content (35) is one mechanism
contributing to lower muscle transcriptional activity and muscle mass with aging, and potentially
leading to sarcopenia in aging. Thus, it is possible that in a similar fashion, reduced proliferation
of satellite cells will contribute to lower nuclear content in skeletal muscle of OZR, which may
have contributed to reduced muscle mass in control muscles compared with LZR. In this study,
satellite cell proliferation was determined by identifying nuclei inside the basal lamina that had
incorporated BrdU during compensatory hypertrophy of the plantaris muscle of OZR and LZR.
We would not expect to see a high number of satellite cells being activated in adult skeletal
muscle in humans under normal basal conditions. However, unlike humans, rodents, continue to
grow throughout their life cycle so one would expect to see a small amount of satellite cell
proliferation even in adult rodent muscles. This expectation was confirmed in our finding of
BrdU positive myonuclei in the LZR control soleus and plantaris muscles. The initial hypothesis
proposed for this study was that satellite cell proliferation would be inhibited in the OZR model
of metabolic syndrome, regardless of loading. This hypothesis was partial confirmed by the
almost complete absence of BrdU positive myonuclei in the control plantaris and soleus muscles
of the OZR.

On the other hand, after loading, the number of BrdU positive myonuclei was

elevated in the LZR, but surprisingly there was an almost equal amount of BrdU positive nuclei
in the loaded plantaris muscle of the OZR and the LZR. We did anticipate that if satellite cell
proliferation was restored it would coincide with a restoration of Akt and myogenic regulatory
factor protein expression as we observed in this study. Previous studies from our lab and others
have shown that loading-induced hypertrophy is accompanied by increases in MyoD and
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myogenin (2,10), whereas, muscle wasting and aging are usually accompanied by decreases or
attenuated increases in protein levels of myogenic transcription factors (2,15,26). In old birds,
the lower levels of myogenic regulatory factors appear to result from reduced contributions from
satellite cells (25); however, restoration of myogenic regulatory factor levels from muscle
loading could reflect changes in both myonuclei and satellite cells (25). In the present study, it is
likely that the increased load on the plantaris muscle was sufficient to increase the activation of
Akt in a contraction dependent manner (32) and that the increase in Akt induced increased
expression of myogenic regulatory factors (23).
Traditional treatments for metabolic syndrome, as recommended by the American
Diabetes Association, include weight loss and aerobic exercise. Aerobic exercise increases
whole-body glucose disposal and improves insulin sensitivity, mainly through increased
expression of GLUT-4 protein (17). However, aerobic exercise is not considered an effective
means to induce skeletal muscle hypertrophy.

On the other hand, resistance exercise has also

been shown to increase glucose transport into the muscle (38) and is widely accepted as a means
to induce muscle hypertrophy.
To the best of our knowledge, this is the first study to demonstrate hypertrophy in an
animal model of metabolic syndrome. It is important to note that metabolic syndrome did not
limit muscle hypertrophic adaptations to increased loading. Another important finding of this
study is that there was a restoration of Akt2 protein expression in hypertrophied muscles of OZR
after overload. Akt2 specifically has been linked to disruptions in GLUT4 regulation, glucose
uptake, as well as skeletal muscle hypertrophy (8,11,31). Skeletal muscle, by virtue of its mass,
is the primary site for glucose and fatty acid oxidation, both of which are important
complications with metabolic syndrome (6,27). These findings suggest that resistance training,
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or some other form of loading, may be a viable addition to the treatment and/or prevention of
metabolic syndrome in humans.
To our knowledge, this is the first study in which satellite cell quantification and
proliferation with metabolic syndrome has been investigated. We do not think that increased
apoptotic signaling could account for the lower number of myonuclei and satellite cells in crosssections of control muscles of the OZR, because we have failed to observe any increases in
markers of apoptosis (TUNEL positive nuclei; protein levels of AIF, Apaf-1, ARC or BAD) in
control muscles of the OZR compared with the LZR. Furthermore, it is unlikely that metabolic
syndrome attenuates the sustained increases in ribosomes, thereby limiting translational capacity,
as is the case in some chronic diseases (1), because in the present study, the plantaris muscles
had similar hypertrophic adaptations to compensatory loading in OZR and LZR. We speculate
that lower Akt and MyoD levels in control muscles of OZR might in turn result in decreased
satellite cell proliferation. This hypothesis is supported by recent data that show that leptin
promotes proliferation and inhibits myogenin expression and myoblast differentiation in vitro
(39), and therefore the lack of leptin might result in an inhibition of satellite cell proliferation. In
the current study, there was a significant decrease in the protein expression of myogenic
regulatory factors, myogenin and MyoD, as well as Akt, which could account for the decreased
satellite cell proliferation in the control muscles of the OZR. It is not clear if the lower levels of
MyoD and Akt are leptin dependent or independent, or simply a response to or a consequence of
metabolic syndrome. Thus, it is possible that deficient leptin signaling or some other aspect of
metabolic syndrome attenuates the expression of these proteins. To test this further, other models
of obesity and metabolic syndrome would need to be investigated in which leptin levels were
manipulated. Nevertheless, in the current study, MyoD, myogenin, and Akt protein expression
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were restored with loading, indicating that a significant stimulus, such as compensatory loading,
is capable of overriding the attenuation of these proteins. Our results show that overloadinduced muscle hypertrophy and satellite cell proliferation occurs at similar levels in skeletal
muscles of OZR and LZR, suggesting that satellite cell function per se is not limited in metabolic
syndrome.
In conclusion, our data suggest that satellite cell proliferation is suppressed in control
muscles of OZR with metabolic syndrome. This may lead to an impaired replacement of nuclei
during normal turnover, and in turn, may contribute to the reduced number of myonuclei per
muscle and the lower muscle mass in animals with metabolic syndrome. These findings
underscore the need for further research to more fully understand the mechanisms responsible for
attenuated satellite cell proliferation in control muscles in the OZR and to determine if satellite
cell activity or proliferation is reduced in other models of the metabolic syndrome.
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Table 1 Animal characteristics.
LZR

OZR

Body weight (g)

296 + 17

497 + 78*

Plantaris control (mg)

272 + 14

220 + 18*

Soleus control (mg)

167 + 20

144 + 9*

Glucose (mg/dl)

100.7 + 49

193.2 + 44

LZR, lean Zucker rats; OZR, obese Zucker rats. *=significant vs. LZR Data reported as mean +
SE.
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FIGURE LEGENDS
Figure 1. A compensatory load was placed on the plantaris muscle by denervating the soleus
and gastrocnemius muscles. The contra-lateral control muscle received a sham surgery. The data
shown are the percent change in the muscle wet-weight in the loaded plantaris, with 7- or 21days of loading, compared to the contralateral control. The effect of loading on muscle wetweight was determined by comparing muscle wet-weights from control and loaded limbs. The
percent change in muscle wet weight was calculated for each individual animal and the means
from these data are presented for each animal group (n=6/group). After 7-days of loading the
percent change in muscle weight was not significant in either the LZR or OZR, however at 21days of loading the percent change in both phenotypes was significant. Data presented as mean +
SE. *, p <0.05 vs. contralateral control. Abbreviations: LZR, Lean Zucker rat; OZR, Obese
Zucker rat; -7, 7 days of loading; -21, 21 days of loading.

Figure 2. Quiescent satellite cells were labeled with a Pax7 antibody and reported as a percent
of the total myonuclei in the control plantaris and soleus muscles. Myonuclei were identified
with DAPI and quantified if they were located within the basal lamina. Representative images of
muscle cross-sections are shown with antibody labeling to Pax7 only (A); Pax7 plus the DAPI
nuclear stain (B); and Pax7, DAPI, and Laminin antibody labeling (C). Each Pax7 positive
nuclei was counted in 6 non-over-lapping microscopic fields. The data were normalized to the
total number of nuclei in the same number of fields to obtain the percent of Pax7 nuclei as a
percentage of total myonuclei. There was no difference in the proportion of Pax7 positive nuclei
to total myonuclei between the LZR and OZR in either the plantaris or soleus muscles (D). In
addition, the numbers of myonuclei for each muscle-fiber cross section were also examined.
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There were a significantly lower amount of nuclei in cross-sections of muscle fibers in the OZR
compared to the LZR in both soleus and plantaris muscles (E). Data presented as means + SE. *,
p < 0.05 OZR (n=12) vs. LZR (n=12). Abbreviations: LZR, Lean Zucker rat; OZR, obese Zucker
rat.

Figure 3. Representative immunoblots of apoptotic signaling proteins in control plantaris
muscles from the lean Zucker rat (LZR) and the obese Zucker rat (OZR). There were no
differences between the content of these proteins in muscles of OZR and LZR (quantification of
blot data are not shown) .

Figure 4. A representative immunofluorescent image (green) of BrdU stained with Alexa-488
(A), BrdU labeling as in A coupled with and a DAPI (blue) nuclear stain (B), and incubated with
a (red) rhodamine conjugated anti-Laminin IgG2a antibody (C). Labeling of BrdU (green),
Laminin (red), and DAPI (blue) was used to identify the BrdU-positive nuclei within the muscle
fibers to estimate the proliferation of muscle satellite cells in 6 non-overlapping fields. The
number BrdU positive nuclei are shown as a percentage of all muscle nuclei in the plantaris (D)
and soleus muscles (E). Only the BrdU positive nuclei within the basal lamina were quantified.
The BrdU labeling index was calculated as the number of BrdU labeled nuclei

.

total nuclei-1 .

100. This provided an index of satellite cell proliferation. The data for the soleus muscles are
control values only, loading experiments were performed only on plantaris muscles (n=6 for all
groups). Data presented as means + SE. *, p < 0.05 OZR-7 vs. LZR-7, or OZR-21 vs. LZR-21
(comparison between control values at same days post surgery). **, p < 0.05 Loaded vs.
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contralateral control. Abbreviations: LZR, Lean Zucker rat; OZR, Obese Zucker rat; -7, 7 days
of loading; -21, 21 days of loading; control, contralateral control.

Figure 5. Immunoblot analysis of the protein expression levels of the myogenic regulatory
factors MyoD (A) and myogenin (B) in control and loaded plantaris muscles. Data are expressed
as optical density x band area normalized to GapDH. The inset displays representative images
for control and experimental muscles. Data presented as means + SE. *, p < 0.05 OZR-7 vs.
LZR-7, or OZR-21 vs. LZR-21 (comparison between control values at same days post surgery).
**, p < 0.05 loaded vs. contralateral control. Abbreviations: LZR, Lean Zucker rat; OZR, Obese
Zucker rat; -7, 7 days of loading; -21, 21 days of loading; control, contralateral control. (n=6 for
all groups).

Figure 6. Immunoblot analysis of the protein expression levels of total Akt (A), Akt1 (B), and
Akt2 (C) isoforms in control and loaded plantaris muscles. Data are expressed optical density x
band area normalized to GapDH. Inset displays representative images for control and
experimental muscles (D). Data presented as means + SE. *= p < 0.05 OZR-7 vs. LZR-7, or
OZR-21 vs. LZR-21 (comparison between control values at same days post surgery). **, p <
0.05 Loaded vs. contralateral control. Abbreviations: LZR, Lean Zucker rat; OZR, Obese
Zucker rat; -7, 7 days of loading; -21, 21 days of loading; control, contralateral control; OD,
optical density, a.u., arbitrary units. (n=6 for all groups).
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Palmitate increases Bax mediated apoptotic signaling C2C12 myotubes
Jonathan M. Peterson, Yan Wang, Randall W. Bryner, David L. Williamson, and Stephen E.
Alway

Abstract
Mitochondria induced apoptotic signaling in differentiated skeletal muscle in response to
palmitate treatment has been recently reported in L6 myotubes, but it is unknown if Bax
signaling contributes to this phenomenon. Additionally, since palmitate treatment decreases
growth factor mediated Akt activation, the association of Akt activity and Bax-Bcl-2 binding was
also examined. Akt content and phospho-Aktser473 were reduced in C2C12 myotubes after
treatment with palmitate. This reduction in phospho-Aktser473 activity coincided with increased
apoptosis in C2C12 myotubes as shown by a 2-fold increase in DNA fragmentation, a ~5-fold
increase in caspase-3 activity, a 2.5-fold increase in caspase 9 activity, and a 2-fold increase in
cytochrome c release from the mitochondria. Furthermore, there was a small but significant
increase in the amount of the pro-apoptotic protein Bax with palmitate treatment. To determine
if palmitate treatment decreased the ability for Bcl-2 to bind and inhibit Bax, an
immunoprecipitation (IP) assay to Bcl-2 was performed.

IP analysis demonstrated that

palmitate treatment significantly lowered the binding of Bax to Bcl-2, which in turn allows the
pro-apoptotic effects of Bax to proceed. Furthermore, treatment of the C2C12 myotubes with
Bax siRNA was able to attenuate the apoptotic effects of palmitate treatment. Together, these
data show that similar to the L6 cell line, palmitate induces mitochondrial-associated apoptosis in
C2C12 myotubes. Our novel finding is that, palmitate treatment corresponded to reductions in
Akt signaling and induces apoptosis through attenuated Bax-Bcl-2 binding.

CHAPTER 4

Peterson 86

Introduction

Obesity increases the risk for heart disease, hypertension and type 2 diabetes mellitus.
Increased accumulation of intramuscular lipids without corresponding increases in β-oxidation
can lead to insulin resistance dyslipidemia and lipotoxicity Excess lipid accumulation is thought
to lead to increased oxidative stress and dysfunction in cardiac muscle (15, 17) although the role
in skeletal muscle has not been well studied.
Palmitate is the most abundant systemic saturated fatty acid in the circulation, and therefore
it has been used frequently, to examine the effects of saturated fatty acids in dyslipidemia on
various tissues (7, 10, 22, 30, 32). Treatment of different cell types with palmitate in vitro has
resulted in apoptosis (9, 22, 25, 31), and has been found to inhibit Akt/Protein kinase B (Akt)
activity in response to insulin (6, 7, 27). However, shorter carbon chained saturated fatty acids,
i.e. laurate, have been demonstrated not to interfere with Akt signaling (6, 7), but their impact on
apoptosis has not been examined.
Although not previously examined in conjunction with palmitate treatment, one of the
primary ways in which Akt inhibits apoptosis is through control of the B-cell
leukemia/lymphoma-2 (Bcl-2) family. Akt signaling acts directly and indirectly to promote the
binding of the anti-apoptotic protein Bcl-2 to the pro-apoptotic protein Bcl-2 associated X
protein (Bax) (14, 16, 33). Once Bax is released from Bcl-2, there is a Bax-Bax-oligomerization,
that inserts into the mitochondrial membrane, and causes mitochondrial permeabilization (33).
Once the mitochondrial membrane is permeablized, there is a release of proapoptotic factors,
including apoptosis inducing factor (AIF), Smac/Diablo, and cytochrome c (5, 18). When free of
the mitochondria AIF translocate to the nucleus and cause DNA fragmentation independently of
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caspases. Similarly, cytochrome c is released from the mitochondria and results in the activation
of caspase-9 and subsequently caspase-3 which leads to DNA fragmentation and cell death (5,
19).

Lastly, when released from the mitochondria Smac/Diablo attenuates the apoptotic

inhibitory proteins, such as XIAP (13). Once released from the mitochondria, these proteins
function to induce DNA fragmentation and apoptosis.
Palmitate treatment has been shown to induce apoptosis in L6 myotubes (25), and Bcl-2
overexpression has been demonstrated to inhibit palmitate induced apoptosis in a non-muscle
cell lines (9). However, whether palmitate treatment can attenuate the ability of Bcl-2 to bind
Bax has not been examined. Therefore, the purposes of this study were to determine if palmitate
treatment, but not the shorter chain fatty acid laurate: (i) induces apoptotic signaling in mouse
C2C12 myotubes; (ii) results in the release of mitochondrial apoptotic factors cytochrome c,
AIF, and smac/Diablo; (iii) attenuates Bax-Bcl-2 binding; (iv) induces apoptosis that is
dependent on Bax signaling.

Materials and Methods

Cell culture. C2C12 myoblasts were purchased from American Type Culture Collection
(ATCC, Manassas, VA). The cells were cultured in 100 mm polystyrene culture dishes in
Dulbecco Modified Eagle’s Medium (Invitrogen, USA) supplemented with 10% FBS and 1%
antibiotic antimycotic mixture and passaged in 0.25% trypsin. The cells were maintained in a
humidified incubator under an atmosphere of 5% CO2 at 37ºC.

For differentiation into

myotubes, the myoblasts were grown to confluency and transferred to DMEM containing ITS
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liquid media (Sigma-Aldrich, St. Louis, MO). Myotubes were used for experiments following 4
days of differentiation. All experiments were performed in triplicate.
Palmitate (Sigma Chemicals; St. Louis, MO) was administered to cells as described by
Chavez and Summers (6, 7) with dodecanoic acid (laurate) used as a short chain free fatty acid
(FFA) to differentiate the effects of FFAs alone and FFAs which interfere with Akt signaling. .
An additional control group received only the media. Briefly, palmitate was dissolved in ethanol
and diluted in DMEM containing 2% BSA. C2C12 myotubes were incubated with the FFAs
(0.75mM final concentration) in 1% FBS–DMEM for 16 h, washed with DHANKS, and then
incubated with the FFA in serum free DMEM for 2 hours. 1% FBS was reintroduced to the
media 10 minutes prior to collection, except where indicated.
siRNA transfection. The myotubes were transfected with scrambled, nonspecific siRNA
without mammalian homology, or Bax siRNA (Santa Cruz Biotechnology, Santa Cruz, CA)
using Lipofectamine 2000 (Invitrogen Carlsbad, CA). Individual siRNAs (80
pmols/transfection) were transfected using Lipofectamine in serum-free DMEM for 6 hours. A
2x concentration (2%FBS, 4% BSA, and 1.25 mM of palmitate) of media was then added to each
well and the samples were incubated for an additional 12 hours.
Cytochrome c Assay. The extent of cytochrome c that was released from the mitochondria
was determined in a mitochondrial-free cytoplasmic protein fraction as previously described
(28).

C2C12 myotubes were collected after treatment in ice-cold extraction buffer in the

presence of a protease inhibitor cocktail (PIC; Sigma-Aldrich). Briefly, cells were lysed in icecold Mito-buffer (20 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM
EDTA, 1 mM dithiothreitol, 250 mM sucrose, and 0.1 mM phenylmethylsulfonyl fluoride) by
homogenization in a small glass homogenizer with Teflon pestle. The homogenates were
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centrifuged at 800 g to remove nuclei and cell debris and then centrifuged at 16,000 g for 20 min
at 4°C to pellet the mitochondria. The supernate contained the mitochondrial-free cytosolic
protein fraction and this used for determining the release of cytochrome c and Smac/Diablo from
the mitochondria. Purity of the fractions were determine through immunoblot analysis of antiMnSOD (a mitochondrial isoform of superoxide dismutase)and anti-CuZnSOD (a cytosolic
isoform of superoxide dismutase) as previously performed in our laboratory (28), data not
shown.
A cytochrome c ELISA kit (#5265, Medical and Biological Laboratories; Japan) was used to
assess the protein content of cytochrome c in the mitochondria-free cytosol fraction to evaluate
the release of the mitochondrial cytochrome c into the cytosol. The change in color was
monitored at a wavelength of 450 nm using a Dynex MRX plate reader. Measurements were
performed in duplicate with all comparisons performed with the same assay. The cytochrome c
content was analyzed as OD450 per milligram of protein, and then normalized to protein
concentration.
Akt/PKB Activity Assay. Akt/PKB activity was determined by an Akt/PKB Kinase Activity
Kit (EKS-400A; Stressgen, Victoria BC). Because the basal level of Akt/PKB activity was
below the sensitivity of the assay, myotubes were first treated with 100 nM of insulin for 10
minutes before harvesting the cells. The change in color optical density (OD) was measured at a
wavelength of 405 nm by using a Dynex MRX plate reader controlled through PC software
(Revelation; Dynatech Laboratories, CA, USA). Measurements were performed in duplicate. The
OD405 reading was then normalized to the milligrams of protein used in the assay.
Nuclear and cytoplasmic protein extracts. The nuclear and cytoplasmic protein extracts were
obtained using the method described by Rothermel et al. (26) and performed routinely in our lab
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(28). Briefly, the cells were washed 3 times in ice-cold phosphate buffered saline (PBS) then
incubated in lysis buffer (10 mM NaCl, 1.5 mM MgCl2, 20 mM HEPES, pH 7.4, 20% glycerol,
0.1% Triton X-100, and 1 mM dithiothreitol) for 5 minutes at 4ºC. The cells were gently
homogenized in a small glass homogenizer with Teflon pestle. The homogenates were
centrifuged at 1,000 rpm for 1 min at 4°C. The supernatants contained the cytoplasmic protein
fraction and were collected. The remaining nuclear pellet was washed twice in lysis buffer and
then resuspended in lysis buffer containing 0.6 M NaCl. The mixture was incubated for 1 h at
4°C and centrifuged at 14,000 rpm for 15 min at 4°C. The supernatants contained the nuclear
protein fraction. The total protein contents of the cytoplasmic extracts were quantified in
duplicate by using bicinchoninic acid reagents (Pierce, Rockford, IL) and bovine serum albumin
(BSA) standards.
A portion of the cytosolic extract (without addition of protease inhibitors) was stored and
used for fluorometric caspase activity assays, while protease inhibitor cocktail (PIC, SigmaAldrich, St Louis, MO) was added to the nuclear and remaining cytosolic portion for further
analysis.
Signaling protein levels were determined by immunoblotting. Myotubes were washed 3
times in ice-cold PBS then 1x SDS sample buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 6%
glycerol, 1% β-mercaptolethanol, 0.02% bromophenol blue) was added directly to the myotubes.
2x SDS lysis buffer was added to an equal volume of mitochondrial free cytosolic protein extract
or nuclear protein extract, respectively. Samples were lysed with a 25 gauge needle and boiled
for 5 min at 100°C. Samples were separated on a 4-12% gradient polyacrylamide gel (Invitrogen,
USA). Gels were blotted to nitrocellulose membranes (Bio-Rad, Hercules, CA) and stained with
Ponceau red (Sigma Chemical Co, St Louis, MO, USA) to confirm equal loading.
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Membranes were blocked in 5% non-fat milk in Tris buffered saline with 0.05% Tween
20 (TBS-T) and then probed with primary antibodies, against Akt, and Akt Ser473
phosphorylation (Cell Signaling Tech.), Bad, Bax, or Bcl-2 (Santa Cruz Biotechnology, Santa
Cruz, CA), Smac/Diablo, AIF (BD biosciences) and β-tubulin (Abcam, Cambridge, MA) was
also used a loading control. Secondary antibodies were conjugated to horseradish peroxidase
(Chemicon, CA, USA) and signals were developed by chemiluminescence (ECL advance,
Amersham Biosciences) and visualized by exposing the membranes to X-ray films (BioMax MS1, Eastman Kodak, Rochester, NY, USA). Digital records of the films were captured with a
Kodak 290 camera. The resulting bands were quantified as optical density (OD) x band area by
a one-dimensional (1-D) image analysis system (Eastman Kodak, Rochester, NY, USA) and
expressed normalized to ß-Tubulin. The sizes of the proteins were verified by using standard
molecular-weight markers (Bio-Rad, Hercules, CA, USA).
Fluorometric caspase activity assay. Activity of the caspase-9, 3, and 8 were analyzed by a
commercial caspase assay kit (APO-54A-019-KI01, Apotech, Switzerland) according to the
manufacturer’s procedure and as previously performed in our laboratory (28). Caspase-3 and
caspase-9 were measured as indices of mitochondrial induced apoptosis, whereas caspase 8 is a
non-mitochondrial dependent caspase.
Briefly, the cytosolic extract without protease inhibitor was incubated in an equal volume of
assay buffer (50 mM PIPES, 0.1 mM EDTA, 10% glycerol, 10 mM DTT, pH 7.2) with 100 µM
of the fluorogenic 7-amino-4-trifluoromethyl coumarin (AFC)-conjugated substrate (Ac-DEVDAFC, Alexis Corp., San Diego, CA, USA) at 37°C for 2 h. The change in fluorescence was
measured on a spectrofluorometer with an excitation wavelength of 390/20 nm, and an emission
wavelength of 530/25 nm (CytoFluor; Applied Biosystems, Foster City, CA, USA) before and
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after the 2 h incubation. Caspase activity was estimated as the change in mean fluorescence
intensity (MFI) expressed as arbitrary units normalized to protein concentration. Measurements
were performed in triplicate.
DNA fragmentation. A cell death detection ELISA kit (Roche Applied Science, Indianapolis,
IN, USA) was used to quantitatively determine the apoptotic DNA fragmentation by measuring
the cytosolic histone-associated mono- and oligonucleosomes. The change in optical density
(OD) was measured at a wavelength of 450 nm by using a Dynex MRX plate reader controlled
through PC software (Revelation; Dynatech Laboratories, CA, USA). Measurements were
performed in duplicate, with samples from OZR and LZR analyzed at the same time. The OD450
reading was then normalized control samples. Measurements were performed in triplicate.
Bax and Bcl-2 binding. To determine if Bax to Bcl-2 binding corresponded to Akt Ser473
phosphorylation, myotubes were serum starved for two hours with or without the addition of a
commercially available Akt inhibitor (124005, Calbiochem, Germany). 1% FBS was
reintroduced to the media 10 minutes before collection of the myotubes. Similarly, to determine
if the binding of Bax to Bcl-2 was altered with palmitate treatment, Bcl-2 was
immunoprecipitated and the binding of Bax was determined through immunoblot analysis.
After treatment, myotubes were harvested in CHAPS buffer (40 mM HEPES, pH 7.5, 120
mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM -glycerolphosphate, 40 mM NaF, 1.5
mM sodium vanadate, 0.3% CHAPS, 0.1 mM PMSF, 1 mM benzamidine, and 1 mM DTT),
rocked for 20 min at 4°C and then centrifuged at 1,000 g for 10 min at 4°C. An aliquot from the
resulting supernatant was preserved as total protein. The remaining supernatant was incubated
with anti-Bcl-2 (0.2 µg/100 µl; Santa Cruz), and incubated overnight at 4°C. Prior to analysis, the
immune complexes were collected for 1 h at 4°C with a goat anti-mouse BioMag IgG (Quigen,
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310004) beads, blocked with 0.1% nonfat dry milk in CHAPS buffer. The beads were collected
using a magnetic stand and washed with 200 mM CHAPS and 60 mM HEPES. The precipitates
were eluted in 5x SDS sample buffer (250 mM Tris-HCl pH 6.8, 10% SDS, 30% Glycerol, 5%
β-mercaptoethanol and 0.02% bromophenol blue) and then boiled for 5 min. The beads were
collected with a magnetic stand, and the supernatant was collected and subjected to SDS-PAGE.
Statistical analyses. Statistical analyses were performed using the SPSS 10.0 software package.
A one way Analysis of variance (ANOVA) was performed on the difference in all measured
variables. Statistical significance was accepted at P < 0.05. All data are given as means + SE.

Results

Palmitate attenuated Akt signaling. To determine the ability of palmitate pre-treatment to
inhibit Akt phosphorylation, serum was removed from the media for 2 hours, and then FBS was
reintroduced into the media (final concentration was 1% FBS) for 10 minutes. Representative
blots for total Akt, Akt1, Akt2, and Akt Ser473 phosphorylation protein expression levels are
shown in Figure 1A with control, laurate, or palmitate treatment. Total Akt was reduced by 30 +
3% in palmitate treated myotubes compared to control or laurate treated myotubes. There was
also a 41 + 7% decrease in Akt Ser473 phosphorylation in palmitate treated myotubes. In a
separate experiment, palmitate treatment resulted in a 33 + 3% decrease in overall Akt activity in
response to 100 nM insulin (Figure 1B).
Palmitate increased Bax protein concentration. To determine if palmitate treatment affected
the Bcl-2 family protein expression levels, these proteins were examined through immunoblot
analysis. There was no change in content of the pro-apoptotic protein Bad, nor was there any
change in the concentration in the content of the anti-apoptotic protein Bcl-2. However, there
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was a small increase, ~20%, in the protein content of the pro-apoptotic protein Bax (Figure 2).
These data may indicate that the actions of palmitate treatment may be dependent on the increase
of the Bax protein.
Palmitate induced release of mitochondrial apoptotic proteins. The proteins cytochrome c,
AIF, and Smac/Diablo all contribute to apoptotic signaling when they are released from the
mitochondria into the cytoplasm. The addition of palmitate to the myotubes increased the
cytoplasmic content of cytochrome c 2-fold compared to control treatments (Figure 3A). In
addition, palmitate treatment also increased the release of Smac/Diablo and AIF from the
mitochondria (Figure 3B).
Palmitate increased Caspase Activity. Palmitate treatment also resulted in a 5-fold increase
in caspase-3 activity, a 2.5 fold increase in caspase-9 activity, with no change in caspase 8
activity (Figure 4).

These data indicate palmitate induced mitochondria-dependent caspase

signaling because caspase-9 activation is dependent on release of cytochrome c from the
mitochondria, whereas caspase 8 is activated independently of mitochondria outer membrane
permeabilization.
Palmitate induced DNA fragmentation. Because caspase-3 is the effector caspase which,
when activated cleave DNA, we measured DNA fragmentation in C2C12 myotubes. Palmitate
and laurate treatment induced a 7-fold and 3-fold increase in DNA fragmentation, respectively,
compared to control treatment (Figure 5). Palmitate treatment generated a 2.5-fold increase in
DNA fragmentation compared to the shorter chained saturated FFA laurate (Figure 5).
Palmitate induced Bax signaling. Since Akt signaling is significantly reduced with palmitate
treatment, but not laurate, and Akt signaling can contribute to the control of Bax to Bcl-2
binding, an immunoprecipitation to Bcl-2 was performed in the presence or absence of 1% FBS
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and the binding of Bax to Bcl-2 was determined. In control samples, the addition of FBS
increased the amount of Akt Ser473 phosphorylation ~50 fold and corresponded to an increase
binding of Bax to Bcl-2 of ~10-fold compared to serum starved samples (Figure 6A). However,
treatment of samples with palmitate, but not laurate, greatly attenuated the Bax to Bcl-2 binding
in response to FBS (Figure 6B).
Bax siRNA attenuated palmitate mediated apoptosis. As expected, treatment with Bax siRNA
reduced Bax protein content in both control and palmitate treated myotubes (Figure 7A). The
reduction in Bax protein expression with siRNA attenuated the increase in DNA fragmentation
and caspase activity that otherwise occurred after palmitate treatment (Figure 7B-D).

In

addition, we noted that the siRNA transfection protocol induced a 2-fold increase in DNA
fragmentation compared to untreated controls (data not shown).

Discussion

The novel findings of this study are: (i) both palmitate and laurate treatment increased DNA
fragmentation indicating that saturated FFA can induce apoptosis (ii) palmitate, but not laurate,
treatment increased mitochondria mediated apoptosis in C2C12 myotubes as indicated by
increased the release of cytochrome c, Smac/Diablo, and AIF from the mitochondria indicating
both caspase dependent and caspase independent apoptotic mechanisms with palmitate
treatment; (iii) palmitate, but not laurate, treatment inhibited Akt activity and attenuated the
ability of FBS to increase Bax-Bcl-2 binding in C2C12 myotubes; and (iv) knock down of Bax
protein significantly attenuated the ability of palmitate treatment to induced apoptosis in C2C12
myotubes. Pre-treatment of C2C12 myotubes with palmitate has been used to mimic aberrant
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lipid signaling. which is one particular aspect common with metabolic syndrome and type 2
diabetes (6, 7, 9, 25, 27). Palmitate, and other long chain saturated FFAs, result in increased
formation of ceramide, which inhibits Akt activity, whereas laurate and other saturated short
chain FFAs do not result in ceramide accumulation or Akt inhibition (6, 7, 21).

This is

noteworthy because ceramide levels are elevated in insulin-resistant humans subjects (1).
Because Akt signaling is both disrupted with metabolic syndrome (6, 7) and has a major role in
inhibiting apoptosis (11, 12, 16), we hypothesized that palmitate would decrease Akt
phosphorylation and activate mitochondrial-associated apoptotic signaling in mouse C2C12
myotubes. Specifically, we hypothesized that palmitate would increase mitochondrial-associated
apoptosis through attenuation of Bax to Bcl-2 binding.
It has been well documented that skeletal muscle apoptosis is an integral part of skeletal
muscle loss with aging (2, 29); the role of skeletal muscle apoptosis in metabolic syndrome has
not been examined. Palmitate treatment has recently been shown to induce mitochondrial DNA
damage and apoptosis in L6 myotubes (25), however this study did not determine whether a
shorter carbon chain FFA, such as laurate, would also induced DNA damage or apoptosis. In our
hands, both laurate and palmitate resulted in increased DNA damage. Nevertheless, palmitate
resulted in augmented apoptotic signaling compared to laurate treatment, signifying that
palmitate treatment induces additional apoptotic signaling compared to shorter FFAs. It is likely
that the decrease in Akt signaling after palmitate treatment contributes to the increase in
apoptosis when compared to laurate treatment. However, it is also possible that palmitate, or its
metabolites, allosterically interfere with Bax and Bcl-2 binding. These possibilities are both
supported by our data, but either situation supports our hypotheses that palmitate induces
mitochondrial apoptosis and that it is dependent on Bax signaling.
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Mitochondrial associated apoptosis in C2C12 cells. When the mitochondrial outer
membrane is permeabilized, it releases proapoptotic factors, such as AIF, Smac/Diablo, and
cytochrome c, each of which can independently increase apoptosis (5, 18). When released from
the mitochondria, AIF translocates to the nucleus where it can cleave the DNA directly.
Smac/Diablo, binds and prevents the actions of a number of apoptosis inhibitory proteins. In
contrast, cytochrome c forms a complex with Apaf-1 and pro-caspase-9 to form the apoptosome.
The apoptosome cleaves pro-caspase-9 into its active form. Caspase-9 then activates caspase-3,
an apoptotic effector that leads to DNA fragmentation and cell death (5, 19). The results of the
present study confirm that palmitate treatment increased nuclear apoptosis in C2C12 cells. This
was confirmed through increases in nuclear levels of AIF, increased cytoplasmic levels of
cytochrome c and Smac/Diablo, and elevated caspase-9 and -3 activity levels, and lastly,
increased DNA fragmentation (Figures 3-5). The reason for increased DNA fragmentation with
laurate treatment compared to controls is unknown, but may be due to increased lipid oxidation
(20, 31). Nevertheless, the increase in DNA fragmentation with laurate treatment is independent
from any apoptotic signaling mechanisms examined in this study.
Bax: Bcl interactions in palmitate treatment. The primary novel finding of this study was that
palmitate treatment, attenuated the ability of growth-factor-rich serum (FBS) to increase BaxBcl-2 binding (Figure 6B). When growth factors were removed from the culture medium, Bax
was dissociated from Bcl-2 but this was quickly reversed (~10 min post treatment) when growthfactor-rich serum was reintroduced to the culture medium (Figure 6A). The pattern of Bax and
Bcl-2 during palmitate treatment coincides with the amount of Akt phosphorylation. In addition
the Bax-Bcl-2 binding was prevented when an Akt inhibitor was added to the media. This
supports the hypothesis that Akt directly acts on Bax to increase its binding to Bcl-2 (8). Once
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Bax is released from Bcl-2 there is a Bax-Bax-oligomerization. This Bax-Bax protein complex
then inserts into the outer mitochondrial membrane, causing mitochondrial permeabilization and
release of proapoptotic factors: AIF, Smac/Diablo, and cytochrome c (33). The release of these
proteins from the mitochondria results in DNA fragmentation and loss of the nucleus (5, 19).
Although the loss of only a few nuclei will not result in elimination of the entire myotube, the
loss of sufficient numbers of nuclei in a single myotube would result in cell death.
Metabolic syndrome is the most prevalent metabolic health risk in the world, affecting more
than 47 million Americans (23). Skeletal muscle is an important target tissue in the study of
metabolic syndrome as it accounts for more than half of total body insulin resistance, and is also
a key tissue for lipids uptake and oxidation (3, 4, 24). Therefore, the loss of skeletal muscle can
further exacerbate the risks associated with metabolic syndrome. In this study C2C12 myotubes
were used as an in vitro model of skeletal muscle and palmitate was used to mimic one aspect
common in metabolic syndrome, dyslipidemia.

This study demonstrated that long chain

saturated fatty acids, i.e. palmitate, can reduce Akt signaling and increase Bax-mediated
mitochondrial induced apoptosis. These findings indicate that people with metabolic syndrome
may have increase apoptotic signaling and underscores the need for in vivo studies examining the
effects of Akt signaling, skeletal muscle apoptosis, and metabolic syndrome.
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Figures Legends
Figure 1: A) Akt protein and Akt Ser473 phosphorylation expression in C2C12 myotubes.
Palmitate treatment significantly reduced the protein expression of Akt as well as Akt Ser473
phosphorylation. Graph shows mean + SE presented as optical density (OD) x area expressed in
arbitrary units. B) Akt activity in C2C12 myotubes. Samples were treated overnight in 1% FBS,
then incubated for 2 hours in serum free media. 10 minutes before collection 100 nM of insulin
was added to the media. Palmitate treatment significantly reduced the activity level of Akt. Data
was normalized to total protein content *p < 0.05 verse control samples.
Figure 2: Bcl-2, Bax, and Bad protein expression in C2C12 myotubes. Palmitate had no effect
on either Bcl-2 or Bad protein expression. However, palmitate treatment significantly increased
the amount of Bax protein expression in C2C12 myotubes. The data are expressed as optical
density (OD) x area (in arbitrary units) and they are displayed as mean ± SE. *p < 0.05 vs.
control samples.
Figure 3: Apoptotic signaling proteins released from the mitochondria. Palmitate treatment
significantly increased the release of Cytochrome c (A), Smac/Diablo, and apoptosis inducing
factor (B) from the mitochondria. The data are are displayed as mean ± SE. *p < 0.05, vs.
control samples.
Figure 4: Caspase Activity Assay Figure in C2C12 myotubes. Palmitate treatment significantly
increased caspase-3 and 9 activity. The data are expressed as fluorescent intensity (MFI) per µg
protein and they are displayed as mean ± SE. *p < 0.05 vs. control samples.
Figure 5: DNA fragmentation in C2C12 myotubes. Palmitate treatment significantly increased
the content of fragmented DNA as determined by a cell death ELISA assay. The data are
expressed as optical density (OD) x area (in arbitrary units) and they are displayed as mean ± SE.
*p < 0.05 vs. control samples.
Figure 6: Bcl-2 immunoprecipitation assay of control samples or with the addition of the Akt
inhibitor (A) with and without 1% FBS added following 2 hours of serum starvation. B) After
treatment with palmitate for 20 hours there was a significant decrease in the amount of Bax
protein that was bound to Bcl-2 with the re-introduction of serum to the media. The data are
expressed as optical density (OD) x area (in arbitrary units) and they are displayed as mean ± SE.
*p < 0.05 vs. control samples.
Figure 7: Bax protein expression with Bax or scrambled siRNA and control or palmitate
treatments (A). Bax siRNA attenuated palmitate induced apoptotic signaling as shown by
decreased DNA fragmentation (B), decreased caspase 3 activity (C), and decreased caspase 9
activity (D). The data are expressed as optical density (OD) x area (in arbitrary units) and they
are displayed as mean ± SE. *p < 0.05 vs. Scramble siRNA treated control sample. ** p < 0.05
vs. scrambled siRNA-palmitate treated sample.
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MITOCHONDRIAL APOPTOTIC SIGNALING IS ELEVATED IN CARDIAC BUT
NOT SKELETAL MUSCLE IN THE OBESE ZUCKER RAT AND IS REDUCED
WITH AEROBIC EXERCISE
Jonathan M. Peterson, Randall W. Bryner, Amy Sindler, Jefferson C. Frisbee and Stephen E.
Alway
Abstract
Cardiac and skeletal muscles are both negatively affected by factors linked to metabolic
syndrome including insulin resistance and obesity. Metabolic syndrome has been associated
with increased mitochondrial apoptosis in cardiac tissue; however, the incidence of
mitochondrial apoptosis in skeletal muscle with metabolic syndrome has not been examined.
In this study we examined the effect of obesity and insulin resistance on key proteins
regulating mitochondrial apoptosis in the cardiac and skeletal muscles and their response to
aerobic training. For this study the left ventricle, the soleus, and gastrocnemius muscles were
examined from 16 obese Zucker rats (OZR) and aged matched lean Zucker rats (LZR). Eight
animals of each phenotype were aerobically trained on a treadmill for 9 weeks; the remaining
animals were untrained controls. Cardiac Bcl-2 protein expression level was ~50% lower in
the OZR compared with the LZR, with no difference in either of the skeletal muscles. Bax
protein expression levels were similar in the cardiac and skeletal muscles of the OZR
compared to the LZR.

However, there was a ~7-fold increase in the Bax protein

accumulation in the myocardial mitochondrial protein fraction of the OZR compared to the
LZR. Furthermore, there was an increase in cytochrome c released from the mitochondria,
and a corresponding increase in caspase-9 and caspase-3 activity in the cardiac muscles of
the OZR compared to the LZR. Moreover, DNA fragmentation was elevated ~2-fold in the
cardiac muscles of the OZR, indicating increased apoptosis. There was no change in
cytosolic cytochrome c, caspase activity, or DNA fragmentation in the skeletal muscles of
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the OZR compared to the LZR. Aerobic exercise training reduced Bax protein expression
levels in both LZR and OZR animals and increased Bcl-2 protein expression levels in the
OZR in the cardiac muscles. Furthermore, cytosolic cytochrome c, caspase activity, and
DNA fragmentation were all reduced in the cardiac muscle of the OZR after exercise, with
no change in the skeletal muscles. Combined these data show that mitochondrial apoptosis is
elevated in the cardiac but not skeletal muscles of the OZR, but aerobic exercise training was
effective in reducing cardiac mitochondrial apoptotic signaling.
KEY WORDS: Insulin resistance, Bax, Bcl-2, mitochondrial signaling, muscle wasting

CHAPTER 5

Peterson 113

Introduction
Apoptosis is a highly organized and tightly coordinated biological process, which
plays a vital role in monitoring a variety of non-pathological cellular events (e.g., tissue
turnover). Aberrant regulation of apoptosis has been implicated in the pathogenesis of
certain severe muscle-related diseases including Duchenne and facioscapulo human muscular
dystrophy (21). The molecular events resulting in the activation and subsequent execution of
the apoptotic program is principally controlled under the simultaneous influence of both proand anti-apoptotic signaling which are primarily regulated by specific apoptotic regulatory
proteins.
The B-cell leukemia/lymphoma-2 (Bcl-2) family of upstream regulators of apoptosis
are crucial intracellular checkpoint proteins in the apoptotic signaling pathway (9, 10, 18).
BCL-2 family members, Bcl-2 associated X (Bax) protein and Bcl-2 have been identified as
the main proteins involved in the regulation of mitochondrial-associated apoptotic signaling
particularly as they relate mitochondrial ion channel forming activities. Bax has been
demonstrated to translocate to the mitochondria and expose its N-terminus via a
conformational change upon induction of apoptosis (2, 4, 8, 14, 18, 29). This conformational
change permits the Bax-Bax-oligomerization and insertion of Bax into the outer
mitochondrial membrane (31), which is followed rapidly by the release of the apoptogenic
factors (e.g., cytochrome c) from the mitochondrial intermembrane space (6, 7, 16).
Collectively, Bax oligomerization is thought to be critical for mitochondrial membrane
permeabilization whereas Bcl-2 opposes the pro-apoptotic activity of Bax by preventing BaxBax-oligomerization (2, 18, 31). Although the precise mechanism of Bax-mediated
apoptogenic factor release from the mitochondrial intermembrane space is still under active
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investigation, it is indisputable that Bax plays an important role in promoting the activation
of apoptotic signaling cascades.
Mitochondrial-associated apoptotic signaling including an elevation in the Bax/Bcl-2
ratio has been implicated in muscle wasting and aging-associated losses of skeletal muscle
(1, 23). The obese Zucker (fa/fa) rat (OZR) is used as an animal model for metabolic
syndrome because it exhibits severe skeletal muscle insulin resistance, hyperglycemia, and
hyperlipidemia (12, 32). Recently, myocardial mitochondrial apoptosis has been
demonstrated to be elevated in this model of metabolic syndrome (15, 17).

However,

although the skeletal muscles of the OZR are smaller than the lean zucker rats (LZR),
mitochondrial apoptotic signaling has not been examined in this model Although, metabolic
syndrome has not been linked to skeletal muscle apoptosis it has been linked to skeletal
muscle atrophy (3), additionally, metabolic syndrome has been associated with increased
apoptosis in cardiac tissue (5, 15, 17). It is possible that increased Bax/Bcl-2 ratio, with
metabolic syndrome, contributes to increase susceptibility to apoptosis in cardiac as well as
atrophy in skeletal muscles.
The first purpose of this study was to confirm an increase in mitochondrial apoptotic
signaling in the cardiac muscles of the OZR compared to the LZR and to determine if
mitochondrial apoptotic signaling is elevated in the skeletal muscles of the OZR compared to
the lean phenotype. Furthermore, our lab has previously demonstrated that aerobic exercise
training can reduce apoptotic signaling in both skeletal and cardiac muscles (24). However
the effects of exercise on mitochondrial apoptotic signaling, in a model of metabolic
syndrome, have not been examined in either cardiac or skeletal muscles.

Therefore, the

second purpose of this study was to determine if aerobic exercise training would reduce
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mitochondrial apoptotic signaling in the cardiac and/or skeletal muscles of the OZR model of
metabolic syndrome.

Materials and Methods

Animals
OZR (n=16) and LZR (n=16) (Harlan, Indianapolis, IN) were housed in pathogen-free
conditions, at 20-22°C with a reversed 12:12-h light-dark cycle, and fed rat chow and water
ad libitum throughout the study period. The institutional animal use and care committee from
West Virginia University School of Medicine approved all experiments. The animal care
standards were followed by adhering to the recommendations for the care of laboratory
animals as advocated by the American Association for Accreditation of Laboratory Animal
Care and fully conformed to the Animal Welfare Act of the U.S. Department of Health and
Human Services.

Treadmill exercise
Both the OZR and LZR were randomly assigned into equal groups of sedentary (OZR, n=8;
LZR, n=8) or exercise-trained (OZR-ET, n=8; LZR-ET, n=8). The exercise-trained animals
were trained by running on a motorized rodent treadmill (Columbus Instruments, Columbus,
OH) 5 days weekly for 9 wk at 0% grade. During the first 3 wk of training, the animals
began 15 minutes at a speed of 10m/min, which was gradually increased to 55 min/day at 20
m/min for the OZR-ET and 24 m/min for the LZR-ET. This pace was maintained for the
remainder of the study. Because the OZR animals are heavier, the same running pace would
result in more total work than the lighter LZR. The higher training intensity for the LZR was
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to attempt to match the training intensity of the LZR-ET to the much heavier OZR-ET (~40%
increase in body weight). We have previously shown that this training protocol stimulates a
moderate endurance training effect with a similar ~25% increase in citrate synthase activity
in both the OZR-ET and LZR-ET (12).

Muscles examined
Muscles from control and exercise-trained animals were harvested after anesthetizing the
animals with 2% isoflurane. The gastrocnemius and soleus muscles from each limb were
dissected from the surrounding connective tissues, and 4–5 mm of the left ventricle were
quickly removed and frozen immediately in liquid nitrogen and stored at –80°C until further
analysis.

Western Blots
Total Protein homogenates were prepared in lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl,
1% Nonidet P-40, 0.5% Sodium Deoxycholate, 1 mM EDTA, 0.1% SDS) with the addition
of Protease inhibitor cocktail (PIC; Sigma). Separate mitochondrial and mitochondria free
protein fractions were also prepared according to methods as previously performed in our lab
(25). Briefly, samples were homogenized in mitochondrial isolation buffer (20 mM HEPES
pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol, 250
mM sucrose) with protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA). The
homogenates were centrifuged at 800 x g to remove nuclei and cell debris followed by
centrifugation at 16,000 x g for 20 min at 4°C to pellet the mitochondria. The supernatants
were used as mitochondria-free cytosol. The mitochondrial pellet was washed twice then
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resuspended in total protein lysis buffer for analysis of Bax associated with the mitochondrial
membrane.
Protein contents were quantified in duplicate by using bicinchoninic acid reagents
(Pierce, Rockford, IL, USA) and bovine serum albumin (BSA) standards. 50 µg of soluble
protein was boiled for 4 min at 100°C in Laemmli buffer and separated on a 4-12% gradient
polyacrylamide gel (Invitrogen, USA). The gels were blotted to nitrocellulose membranes
(Bio-Rad, Hercules, CA, USA) and stained with Ponceau red (Sigma Chemical Co, St Louis,
MO, USA) to confirm equal loading and transferring of proteins to the membrane in each
lane.
The membranes were then blocked in 5% non-fat milk in Tris buffered saline with
0.05% Tween 20 (TBS-T) and probed with anti-Bcl-2 or Bax antibodies (Santa Cruz, CA,
USA). Additionally, as a second means of confirming equal loading, the membranes were
also probed for ß-Tubulin (Abcam, MA, USA). Secondary antibodies were conjugated to
horseradish peroxidase (Chemicon, CA, USA) and the signals were developed by
chemiluminescence (ECL advance, Amersham Biosciences). The signals were visualized by
exposing the membranes to X-ray films (BioMax MS-1, Eastman Kodak, Rochester, NY,
USA), and digital records of the films were captured with a Kodak 290 camera. The
resulting bands were quantified as optical density (OD) x band area by a one-dimensional (1D) image analysis system (Eastman Kodak, Rochester, NY, USA) and expressed in arbitrary
units normalized to ß-Tublin.

Cytochrome c Assay
The concentration of cytochrome c in the mitochondrial-free cytosol was measured
with an ELISA kit (Medical and Biological Laboratories; Japan). The change in color was
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monitored at a wavelength of 450 nm using a Dynex MRX plate reader. Measurements were
performed in duplicate with all comparisons performed with the same assay.

The

cytochrome c content was expressed as OD450 per milligram of protein and reported as
relative to LZR control values.

Fluorometric caspase activity assay
To determine whether changes in Bax or Bcl-2 resulted in any downstream apoptotic
events the activity of caspase-3 and caspase-9 were analyzed by a commercial caspase assay
kit (APO-54A-019-KI01, Apotech, Switzerland) according to the manufacturer’s procedure
and as previously performed in our laboratory (24). Briefly, 50 mg of muscle samples were
gently homogenized with a Teflon pestle on ice in 1 ml of nuclear isolation lysis buffer (10
mM NaCl, 1.5 mM MgCl2, 20 mM HEPES, pH 7.4, 20% glycerol, 0.1% Triton X-100, and 1
mM dithiothreitol). The homogenates were centrifuged at 1,000 rpm for 1 min at 4°C. The
supernatants contained the cytoplasmic protein fraction and were collected. The cytoplasmic
protein fraction was then used for the caspase activity assays and also for the cell death
ELISA.
Samples were mixed in equal parts assay buffer (50 mM PIPES, 0.1 mM EDTA, 10%
glycerol, 10 mM DTT, pH 7.2) and then 100 µM of the fluorogenic 7-amino-4trifluoromethyl coumarin (AFC)-conjugated substrate (Ac-DEVD-AFC, Alexis Corp., San
Diego, CA, USA) was added at 37°C for 2 h. The change in fluorescence was measured on a
spectrofluorometer with an excitation wavelength of 390/20 nm, and an emission wavelength
of 530/25 nm (CytoFluor; Applied Biosystems, Foster City, CA, USA) before and after the 2
h incubation. Caspase activity was estimated as the change in arbitrary fluorescence units
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normalized to milligrams of protein used in the assay and data was reported relative to LZR.
All measurements were performed in triplicate.

Cell Death ELISA
A cell death detection ELISA kit (Roche Applied Science, Indianapolis, IN, USA)
was used to quantitatively determine the apoptotic DNA fragmentation by measuring the
cytosolic histone-associated mono- and oligonucleosomes. The change in color was measured
at a wavelength of 450 nm by using a Dynex MRX plate reader controlled through PC
software (Revelation; Dynatech Laboratories, CA, USA). Measurements were performed in
duplicate, with samples from OZR and LZR analyzed at the same time. The OD450 reading
was then normalized to the milligrams of protein used in the assay.

Statistical analyses
Statistical analyses were performed using the SYSTAT 11.0 software package. A one
way Analysis of variance (ANOVA) was performed on the difference in all measured
variables. Statistical significance was accepted at P < 0.05. All data are given as means +
standard error.

RESULTS
Animal Characteristics
Fasting blood glucose, insulin, body weight, citrate synthase activity, and mean
arterial blood pressure have been reported previously (12). These data show that the OZR
used in our study were obese, hyperinsulinemic, hyperglycemic, and hyperlipidemic. This is
consistent with previous studies which observed similar traits in these animals (3, 32).
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Briefly, Nine weeks of treadmill exercise reduced body mass by ~23%, reduced fasting
insulin by ~38%, and reduced plasma triglycerides by ~34% in EX-OZR vs. sedentary (SED)
OZR (12). Additionally, the nine weeks of treadmill exercise use in this study increased
citrate synthase activity ~40% in both phenotypes (12). The mass of the heart, gastrocnemius,
and soleus muscles are reported in Table 1.

Bax protein contents
Bax levels were comparable in cardiac and skeletal muscles of OZR and LZR
animals. However, aerobic exercise reduced Bax levels in the cardiac muscles of the OZR by
35% (Figure 1A). On the other hand, no differences were observed in Bax protein content of
the skeletal muscles either between animal phenotype or between exercise training in either
the gastrocnemius or soleus muscles.

Bcl-2 protein contents
Representative western blots and the quantified optical density and areas of the
protein bands of the anti-apoptotic protein Bcl-2 are shown in Figure 1B. In the heart, Bcl-2
protein expression in the OZR was about half of the Bcl-2 found in the LZR. Additionally,
exercise training increased Bcl-2 protein expression in the OZR hearts by approximately
25%. On the other hand, no differences were observed in Bcl-2 content of the skeletal
muscles between LZR and OZR in either the gastrocnemius or soleus muscles. Moreover,
exercise training had no effect on Bcl-2 protein content in either the gastrocnemius or soleus
muscles.

Bax/Bcl-2 ratio
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The ability for Bcl-2 to inhibit the activity of Bax is dependent on the ratio of these
two proteins. When Bax is in excess, Bcl-2 cannot bind and sequester all the Bax, thus
allowing more Bax to act on the mitochondrial membrane. In the heart there was a 2-fold
increase in the ratio of Bax to Bcl-2 in the OZR compared to LZR (Figure 1C). Aerobic
exercise had a trend towards a decrease in this ratio in the heart of the trained OZR vs.
control OZR (p=0.072). No differences were observed in the Bax to Bcl-2 ratio in either the
soleus or the gastrocnemius muscles among the groups.

Mitochondrial Bax accumulation
To determine if changes in Bax/Bcl-2 ratios resulted in an increase accumulation of
Bax to the mitochondrial membrane of the heart, the mitochondrial protein was isolated in
samples taken from the myocardium. There was a large accumulation of Bax in the
myocardial mitochondrial protein fraction (Figure 3A) of OZR compared to LZR. The
amount of Bax associated with the mitochondrial protein fraction was reduced in the exercise
trained OZR, although there was still a significant accumulation when compared to the LZR.
On the other hand there was no observable accumulation of Bax in the isolated mitochondrial
protein fraction from either the soleus or gastrocnemius muscles regardless of phenotype
(data not shown).

Cytochrome c ELISA
Increased permeability of mitochondrial membranes and opening of the
mitochondrial permeability pore results in cytochrome c release from the mitochondria to the
cystosol. Increased cytosolic cytochrome c has been attributed to caspase-dependent
apoptosis (7). The non-mitochondrial cytosolic protein fractions of cardiac muscles from the
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OZR had a small but significant, ~30%, increase in cytochrome c compared to the LZR
(Figure 5). Aerobic training abolished this increase in cytochrome c accumulation in the
cystosol in cardiac muscles samples of the OZR when compared to the LZR. No differences
were noted in the amount of cytochrome c in the mitochondria-free cytosolic protein fraction
between the OZR and LZR in the gastrocnemius muscles or soleus muscles.

Caspase activity
Caspase 3 and caspase 9 activities were examined to confirm the significance of
increases in the Bax to Bcl-2 ratio in downstream mitochondrial apoptotic signaling in the
cardiac muscle samples. When the mitochondrial membrane is permeablized and cytochrome
c is released, cytochrome c in turn activates caspase 9. When activated, caspase 9 in turn
activates caspase 3 an effector caspase which causes DNA fragmentation and apoptosis. In
this study, both caspase 3 and caspase 9 were elevated by more than 30% in the cardiac
muscle samples of the OZR compared to LZR. Exercise training in the OZR returned the
activity level of both caspases to levels found in the LZR.
There was a significant elevation of both caspase 3 and caspase 9 activities in the
denervated gastrocnemius muscles compared to the intra-animal control muscle. Similar to
the Bax and Bcl-2 protein data, there was no difference in the extent of these changes
between the LZR and OZR.

Cell Death ELISA
To determine whether the observed changes in apoptotic signaling resulted in cell
death, DNA fragmentation was quantified in the cardiac and denervated gastrocnemius
muscles. In the cardiac muscle there was a ~40% increase in DNA fragmentation in the OZR
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compared to the LZR. Exercise training reduced DNA fragmentation in cardiac muscle
samples from the OZR to levels similar to the LZR (Figure 8A). Exercise training had no
effect on the DNA fragmentation in the myocardium of LZR animals.

Discussion

The important finding of this study is that Bax-mediated mitochondrial apoptotic
signaling is elevated in the cardiac but not skeletal muscles of the OZR. This finding was
supported by both an increased Bax to Bcl-2 ratio and an increased Bax protein in the
mitochondrial protein fraction of the cardiac but not skeletal muscles of the OZR.
Furthermore, apoptotic signaling downstream of the mitochondria including cytoplasmic
cytochrome c and caspase 3 and 9 activities were also all elevated in cardiac muscle samples,
as was the level of DNA fragmentation. Furthermore, 9 weeks of treadmill training reduced
apoptotic signaling in the cardiac muscle but had no effect in the skeletal muscles of the
OZR.
It is estimated that the prevalence of metabolic syndrome is greater than 20 percent of
the population in the Unites States (11). Similar to subjects with metabolic syndrome, the
OZR suffers from hyperglycemia, dyslipidemia, and hyperinsulinemia (12, 32). Diabetic
conditions, including hyperglycemia, dyslipidemia, and hyperinsulinemia, have been
demonstrated to cause mitochondrial membrane hyper-polarization and the formation of
reactive oxygen species and apoptosis in cardiac (5, 7, 13, 30) and smooth muscles (27, 28).
Although apoptosis has not been previously examined in diabetic skeletal muscle, we
hypothesized that apoptotic signaling would be similar in skeletal muscle and cardiac muscle.
Since apoptosis is elevated in response to various diabetic conditions, we expected to see
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increased presence of the mitochondrial apoptotic markers Bax, Bcl-2, and cytosolic
cytochrome c in cardiac and skeletal muscles of the OZR as compared to LZR. Furthermore,
because endurance exercise has been shown to attenuate apoptotic signaling (24) we
anticipated a reduction in apoptotic signaling in cardiac and skeletal muscles of OZR with 9weeks of treadmill training.

Bax, Bcl-2 and Bax/Bcl2 ratios in cardiac and skeletal muscles of lean and obese rats.
The ratio of Bcl-2 to Bax is indicative of mitochondrial induced apoptotic potential as
Bcl-2 binds and opposes the pro-apoptotic activity of Bax by preventing Bax conformational
change or translocation to the mitochondria (8, 18, 31).

Once incorporated into the

mitochondria Bax is believed to form a pore in the mitochondria membrane that releases
proteins (e.g. Cytochrome c) which results in a continuation of the apoptotic signaling
cascade (e.g. Caspase 9 and caspase 3) (2, 26, 29). In this study we observed an increase in
the Bax to Bcl-2 ratio and an increased Bax protein in the mitochondrial protein fraction of
the cardiac but not skeletal muscles of the OZR. Furthermore, there was an increase in
cytochrome c accumulation in the cytosol from cardiac muscles but not skeletal muscles in
the OZR compared to the LZR.

Additionally, apoptotic signaling downstream of the

mitochondria including caspase 3 and 9 activities were also elevated in cardiac muscle
samples of the OZR compared to the LZR. This shows that mitochondrial permeability was
increased in the cardiac cells of OZR, and that apoptotic signaling was elevated in the cardiac
muscles samples as well.

Together,

these data may partially explain the increase

susceptibility to ischemia-reperfusion injury as the cardiac muscle is more prone to apoptosis
with metabolic syndrome (5, 13).
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Exercise improves apoptotic signaling in the myocardium of lean and obese rats.
The second part of this study was to determine the impact that 9-weeks of treadmill
exercise would have on the Bax to Bcl-2 ratio and associated apoptotic signaling. The
influence of exercise training on apoptosis has not been fully examined, and only a few
studies have attempted to define the relationship of acute strenuous exercise with apoptosis in
skeletal muscle (19, 20). Siu and colleagues (24) found reduced DNA fragmentation in
ventricle and soleus samples of trained animals when compared to control animals.
Furthermore, both mRNA and protein contents of Bcl-2 increased in both soleus and
ventricle muscles of endurance trained animals when compared with control animals.
However, Bax mRNA levels decreased in the soleus of exercise trained animals when
compared with control animals. In the present study we observed a tread towards a decreased
Bax to Bcl-2 ratio (p=0.072) with 9-weeks of treadmill exercise in the cardiac muscle
samples of the OZR. In addition we observed a significant decrease in the amount of Bax in
the mitochondrial protein fraction (~50% reduction) of the cardiac muscle samples of the
OZR after exercise training. Furthermore, we observed a reduction in both caspase 9 and 3
activities in the myocardium of the OZR with 9-weeks of treadmill exercise. Together, these
data indicate that aerobic exercise prevents mitochondrial apoptotic signaling in cardiac
muscles of OZR.
Additionally, we have found that the Bax/Bcl-2 ratio was similar in LZR and OZR
skeletal muscle samples and exercise did not improve this ratio. These data suggest that
metabolic syndrome may have a different effect in skeletal verses cardiac muscles.
Furthermore, these data suggest that skeletal muscle is more resistance to exercise-induced
improvements in apoptotic signaling than cardiac muscle. We cannot rule out the possibility
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that more intense or longer exercise training parameters may have improved apoptotic
signaling in skeletal muscles of the LZR or the OZR animals. Previous training studies in
our lab were performed with a treadmill speed of 28 m/minute, compared to 24 for the LZR
and 20 for the OZR (the OZR would not comply with faster pace). Nevertheless, the exercise
parameters in this study were sufficient to induce improvements in citrate synthase activity
(12), and mitochondrial protein (Cytochrome c Oxidase, unpublished).
Sandri and colleagues investigated the influence of acute intense exercise on
apoptosis in skeletal muscles of both young normal and dystrophin-deficient (mdx) mice
(20). They found that the DNA double strand breaks (as an indicator of DNA fragmentation)
measured by in situ terminal deoxynucleotidyl transferase-mediated nick end labeling
(TUNEL) increased by ~20%, 48 h after a night of spontaneous wheel running in both
normal and mdx mice skeletal muscles. Using DNA gel electrophoresis, they reported that
the amount of fragmented chromosomal DNA was greater in the skeletal muscles from mdx
mice after the 16 h spontaneous wheel running when compared with their non-exercise
partners. The same laboratory reported that TUNEL-positive myonuclei existed after 16 h of
spontaneous running in skeletal muscles of both C57B and mdx mice (22). Furthermore, they
found that Bcl-2 protein levels decreased after spontaneous exercise in muscle of mdx mice.
Similar results of increased apoptotic nuclei and a decreased ratio of Bcl-2/Bax have also
been documented in skeletal muscles after a 16 h spontaneous wheel running in normal
healthy animals (19). Activation of apoptosis in muscle tissue following acute bouts of
exercise is not fully understood; however, these studies suggest that strenuous exercise may
induce apoptosis in skeletal locomotion muscles. In our study the animals were trained
gradually and for 9-weeks. We did not observe any increased apoptotic signaling with
exercise in skeletal or cardiac muscles of OZR based on Bax, Bcl-2 or DNA fragmentation
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data. It is possible that an acute bout of exercise may have altered apoptotic signaling
proteins in either cardiac or skeletal muscles; however that was beyond the scope of this
paper.
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LZR (n = 8)

LZR-ET (n = 8)

OZR (n = 8)

OZR-ET (n = 8)

945±82
174±12
1698±104

923±83
168±10
1645±124

1052±98*
149±11*
1298±140*

1143±71*
140±14*
1229±153*

Table 1: Values are means ± SE; n, no. of animals. LZR, lean Zucker rat; EX, exercise; OZR,
obese Zucker rat. * p<0.05 vs. LZR.
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Figure Legends
Figure 1. Average Bax and Bcl-2 protein expression are shown in the heart, soleus, and
gastrocnemius muscles of lean (LZR) and obese (OZR) animals. The inserts show
representative western blots for Bax (A) and Bcl-2 (B) from LZR and OZR rats with or
without 9 weeks of endurance exercise. Equal protein loading was confirmed for all samples
by normalizing optical density to ß-tubulin for the each protein sample. The gels were
scanned densitometrically and the area and optical density of each band was determined.
Data for each protein band were calculated as optical density x band area, normalized to the
β-tubulin band. (C) The Bax/Bcl-2 ratio is shown for heart, soleus and gastrocnemius muscle
samples from LZR and OZR rats after 9 weeks of endurance exercise. All data are reported
as means ±SE. * p<0.05 OZR vs. LZR; ** p<0.05 OZR exercise vs. OZR control.

Figure 2. To verify that the increase in Bax-to-Bcl-2 ratio resulted in an increase
translocation of Bax to the mitochondrial membrane, mitochondria protein was isolated from
the heart tissue. The data are expressed relative to LZR data for each muscle. The data show
that cardiac mitochondrial Bax was greater in the OZR than the LZR but mitochondrial Bax
was lower in cardiac muscle samples taken from exercise trained (ET) OZR compared to
sedentary animals. All data are reported as means ±SE. * p<0.05 OZR vs. LZR; ** p<0.05
OZR exercise vs. OZR control; ** p<0.05 OZR exercise vs. obese and lean control.

Figure 3. A cytochrome c ELISA was conducted on cardiac muscle samples from control
and exercise trained (ET) LZR and OZR rats. Protein concentration of the sample was
determined by the BCA assay. The cytochrome c data are expressed as ng•µl muscle protein-
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. All data are reported as means + SE. * p<0.05 OZR vs. LZR; ** p<0.05 OZR exercise vs.

OZR control; ** p<0.05 OZR exercise vs. obese and lean control.

Figure 4. Caspase 3 and 9 activities were determined on cardiac muscle samples from
control and exercise trained (ET) LZR and OZR rats. Activities are expressed relative to
protein concentration. All data are reported as mean ±SE. * p<0.05 vs. LZR control; **
p<0.05 vs. OZR control.

Figure 5. DNA fragmentation was determined on cardiac muscle samples from control and
exercise trained (ET) LZR and OZR rats. Optical density of the assay was recorded and
reported relative to protein concentration. All data are reported as means ±SE. * p<0.05 vs.
LZR control; ** p<0.05 vs. OZR control.
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Additional DATA for specific aim 4, not yet published
METHODS
Denervation procedure
Hindlimb denervation was performed on a separate cohort of animals as routinely performed
in our lab (1, 23). Briefly, the animals were placed under a general anesthesia using 2%
isoflourene, and after cessation of reflex activity, the tibial nerve was dissected proximal to
the cranial border of the gastrocnemius muscle. Care was taken to avoid any damage to the
nerves, blood vessels and connective tissues. The medial and lateral branches of the tibial
nerve that innervate the plantar flexor muscles (i.e. gastrocnemius and soleus) were cut, and
the cut nerve ends were sutured into the biceps femoris muscle to ensure that the nerve
stumps did not reinnervate the gastrocnemius muscle. Innervation to the plantaris and the
deep toe flexor muscles were left intact so that the animals ambulated normally around the
cage after the surgical denervation. Following the surgery, the hamstring muscle layers were
closed with reabsorbable suture, and the skin incisions were closed with wound clips. The
incision sites were covered with an antibacterial cream to prevent infection. The contralateral
limb served as the intra-animal control. We have observed that the animals recovered quickly
and were able to walk around within 45 min post surgery (1). Withdrawal of innervation to
the medial gastrocnemius results in an highly-favorable apoptotic environment for this
muscle (23).
Muscles examined.
Muscles from Control and exercise-trained animals were harvested after anesthetizing the
animals with 2% isoflourene and then euthanized by decapitation. The medial gastrocnemius
and soleus muscles from each limb were dissected from the surrounding connective tissues,
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and 4–5 mm of the apex cordis from the heart was quickly removed and frozen immediately
in liquid nitrogen and stored at –80°C until further analysis.
In the second cohort of animals the gastrocnemius muscles was collect seven days
after the surgical denervation, animals were anaesthetized using 2% isoflourene and the
animals were then euthanized by decapitation. The gastrocnemius muscles from each limb
were dissected from the surrounding connective tissues, removed, and stored at –80°C.
Animals were subsequently euthanized via cardiac puncture.

RESULTS

Denervated Gastrocnemius Muscle. As neither obesity nor exercise training altered the
Bax or Bcl-2 content in the skeletal muscle an additional cohort of animals was added in
which the gastrocnemius muscle was denervated to induce an apoptotic response (1). Seven
days of denervation resulted in a ~30% increase in the Bax protein content in the
gastrocnemius muscle of both the LZR and OZR. There was also a non-significant increase
the Bcl-2 content in both phenotypes which resulted in denervation demonstrating no
increase in the Bax to Bcl-2 ratio (figure S1).

Caspase activity. To confirm the significance of increase Bax to Bcl-2 ratio in downstream
mitochondrial apoptotic signaling caspase 3 and caspase 9 activities were examined. In the
denervated gastrocnemius muscles there was a significant elevation of both caspase 3 and
caspase 9 activities compared to the intra-animal control. Similar to the Bax and Bcl-2
protein data there was no difference in the extent of these changes between the LZR and
OZR.
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Cell Death ELISA. To determine whether the observed changes in apoptotic signaling
resulted in cell death, DNA fragmentation was quantified in the cardiac and denervated
gastrocnemius muscles. With denervation there was a significant increase (~1.5 fold) in
DNA fragmentation for both the LZR and OZR compared to the intra-animal control limb.
However, in agreement with the Bax and Bcl-2 data, there was no difference in the
magnitude of these changes between the LZR and OZR.

DISCUSSION

It was rationalized that in young adult OZR the effects of obesity may not sufficient
to reveal differences in apoptotic signaling between the LZR and OZR.

However, if

apoptosis was induced in skeletal muscle we expected that the OZR would have a magnified
apoptotic signaling response compared to LZR. To induce skeletal muscle apoptosis we
denervated the rat gastrocnemius because we have previously shown that this approach
induces apoptosis (1). However, although denervation resulted in nuclear apoptosis in this
experiment, there was no difference in the magnitude of change between the intra-animal
controls of the LZR verses the OZR. Contrary to our hypotheses, these data suggest that
obesity and metabolic syndrome does not exacerbate apoptotic signaling in skeletal muscle.
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Figure S-1. Representative western blots for Bax and Bcl-2 (A) in denervated and control
gastrocnemius muscles from LZR and OZR are shown in the figure insert. Equal loading
was confirmed for all samples by normalizing optical density to ß-tublin for the each protein
sample. The gels were scanned denistometrically and the area and optical density of each
band was determined. Data for each protein band were calculated as optical density x band
area, normalized to the β-tubulin band. The Bax/Bcl-2 ratio denervated and control
gastrocnemius muscles from LZR and OZR (B). All data are reported as means + SE. *
p<0.05 OZR vs. LZR.
Figure S-2. Caspase 3 and 9 activities were determined in control and denervated
gastrocnemius muscles of LZR and OZR. Activities are expressed relative to protein
concentration. All data are reported as means ±SE. * p<0.05 vs. LZR control, ** p<0.05 vs.
OZR control.
Figure S-3. DNA fragmentation was determined in control and denervated gastrocnemius
muscles of a second cohort of LZR and OZR. Optical density of the assay was recorded and
reported relative to protein concentration. All data are reported as means ±SE. * p<0.05 vs
LZR control, ** p<0.05 vs. OZR control.
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DISCUSSION
Findings and Conclusions from this project
The studies in this dissertation examine the contribution of satellite cell activation,
differentiation, and myonuclear apoptosis for maintenance of the myonuclear domain and
skeletal muscle hypertrophy in models of metabolic syndrome and obesity. The primary finding
was that there was a significant decrease in proliferation and differentiation of C2C12 myoblasts,
an in vitro model of satellite cells, when the cells were incubated with palmitate, a primary lipid
that is upregulated in obesity and the metabolic syndrome. Furthermore, there was also a
significant decrease in satellite cell activation in control muscles of the OZR compared with the
LZR. The decreased proliferation and differentiation, in vitro, and the decreased satellite cell
activation, in vivo, corresponded to attenuated Akt signaling in both models of obesity and the
metabolic syndrome. It is possible that the decreased Akt protein expression in these models
accounts for the attenuation of myoblast/satellite cell activation and differentiation. In support of
this hypothesis, Akt protein expression increased in response to compensatory loading, and there
was no difference in the amount of satellite cell activation in loaded muscles of the OZR
compared with the LZR. It is likely that the increased load placed on the plantaris muscle by
denervation of its synergists was sufficient to induce an increase in Akt protein expression in the
OZR (17, 18), and the enhanced Akt protein expression was sufficient for the increase in satellite
cell activation in the OZR.

Role of palmitate in regulation of myoblasts and myonuclei
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The data presented in this dissertation clearly show that palmitate treatment has the
capability to induce apoptosis in C2C12 myotubes. Furthermore, Akt activity is inhibited by
palmitate in C2C12 cells and this is consistent with observations in other studies (3, 4).
However, an apoptotic stimulatory role for palmitate in muscles of animals with metabolic
syndrome does not appear to be important in vivo. Although Akt activity was reduced in the
skeletal muscles of the OZR compared to the LZR, there was no increased incidence of apoptosis
or apoptotic signaling. The absence of apoptotic signaling in the skeletal muscles of the OZR
was surprising. However, in addition to increased circulating levels of fatty acids, the OZR have
a variety of other factors that may have acted to protect the skeletal muscle from the negative
effects of palmitate. One example of this is the elevated UCP3 protein expression observed in
the OZR compared to the LZR (see supplemental data). UCP3 is believed to protect the
mitochondria from free fatty acid-induced damage (12, 20). Comparatively, in our hands
palmitate-treated myotubes showed no increase in UCP3 protein expression.

Another

explanation for the possible lack of apoptosis in the skeletal muscles of the OZR could be the
fact that although the OZR have elevated palmitate levels, there is also an increase in the amount
of unsaturated free fatty acids as well. It has been proposed that unsaturated free fatty acids may
have a protective role and help stabilize and/or slow down the metabolism of saturated free fatty
acids (22).
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Limitation and Future Directions
The rationale for this project was that reduced skeletal muscle mass with metabolic
syndrome would be detrimental, because skeletal muscles are the primary tissue in regards to
glucose and fatty acid oxidation (1, 2, 16). Disruptions of either glucose or fatty acid oxidation
are major contributors to complications associated with obesity and the metabolic syndrome.
Understanding the mechanism in which obesity and the metabolic syndrome may inhibit skeletal
muscle growth may lead to treatment options aimed at improving skeletal muscle growth and
hypertrophy.
The design of this study specifically focused on examining the mechanism to explain the
smaller skeletal muscles in the OZR compared to the LZR. This study design also examined the
effects of the saturated free fatty acid palmitate on myoblasts (an in vitro model of satellite cells)
and myotubes (an in vitro model of mature skeletal muscle). Palmitate was selected because the
OZR have a significantly higher plasma and intramuscular concentration of palmitate compared
to the LZR (13, 21). Furthermore, palmitate has been previously shown to be sufficient to inhibit
Akt activity due to it’s metabolite ceramide (3, 4).
Although the selection of palmitate in vitro was appropriate for this study, it also
accounts for one limitation of this study design. High palmitate levels are not the only difference
between the OZR and LZR. Future in vitro studies should focus on other aspects of metabolic
syndrome besides higher palmitate levels. For example, non-saturated free fatty acids, which are
also elevated in the OZR, have different metabolites and have been demonstrated to stabilize the
saturated fatty acids and may protect the cells from apoptosis (4, 10, 11, 19). To test this
hypothesis the monounsaturated fatty acid oleate would be added to the media to determine
whether it protects the myotubes from apoptotic signaling induced by palmitate. The co-
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incubation of oleate with palmitate has been previously demonstrated to reverse palmitateinduced insulin resistance and inflammation in skeletal muscle cells (7). The research design for
testing the effects that oleate would have on reversing palmitate mediated apoptotic signaling in
C2C12 myotubes would be performed in five groups as follows: (i) Palmitate only (0.075 mM),
(ii) Palmitate and Oelate (0.75 mM of each), (iii) Palmitate and Oelate (0.375 mM of each), (iv)
Oleate only (0.75 mM), and (v) Laurate (0.75 mM).
The findings of this study demonstrated that elevated palmitate was sufficient to inhibit
skeletal muscle proliferation and differentiation, at least in vitro. However, besides increased
palmitate levels, the OZR also has increased levels of adipokines, particularly leptin.

To

determine whether these additional adipokines, (i.e. Leptin) also interfere with myoblast
proliferation and differentiation this study design will be repeated with the addition of adipokines
to the cells and their influence on proliferation and differentiation would be determined.
Together, understanding the affects of these adipokines may be beneficial for understanding
additional mechanism in which obesity and the metabolic syndrome may interfere with skeletal
muscle growth and hypterophy.
Although the OZR is a well established genetic model of obesity and metabolic
syndrome, follow-up studies using diet induced obesity could be performed. Briefly, animals
would be divided into a normal chow diet (10% calories from fat) compared to high-fat diet
(60% calories from fat and fed ad libitum for 9 weeks, as performed by others previously (5, 8,
23). After nine-weeks of feeding, the BrdU implantation procedure preformed in this study
would be repeated in these animals.
Although satellite cell activation was reduced in the unloaded skeletal muscles of the
OZR compared to the LZR, we were able to induce significant satellite cell activation with
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compensatory loading. This highlights another limitation of the present study as compensatory
loading is a physiological, but severe, loading model that would be unrepeatable in translationa
research. This was the first study to demonstrate hypertrophy in a rat model of obesity and the
metabolic syndrome, and demonstrates that hypertrophy and satellite cell activation is possible.
However, future work needs to be done to determine if less severe models of loading could also
restore satellite cell activation. For example, Cutlip et al. have develop a chronic exposure to
stretch-shortening contractions model in rats using a dynamometer for testing mal-adaptation in
young verse old rats (9). This model could be used in OZR, or in high-fat fed rats, to test for maladaptation or satellite cell activation (through BrdU incorporation).
It would be important to discover if there is a decrease in the satellite cell activation in
young developing adolescents. The results of the National Health and Nutrition Examination
Survey 2003-2004 indicate that the prevalence of obesity is increasing, especially in young
people, effecting approximately 17% of Americans 2-19 years of age (6, 14, 15). With increased
obesity there is an elevation of lipids in the circulation, similar to that observed in the OZR. It
would be important to discover if there is a decrease in the satellite cell activation in young
developing adolescents and to discover if this could be restored with loading (resistance
training). These data may provide important information in developing treatment strategies for
obese adolescents and alter the way in which obesity and the metabolic syndrome is managed.
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ABSTRACT
Uncoupling protein 3 (UCP3) is a mitochondrial inner membrane protein which is thought to shuttle nonmetabolize fatty acids, particularly when there are excessive fatty acids present. PURPOSE: Obese
zucker rats (OZR) have systematically elevated levels of fatty acids, with decrease fatty acid metabolism.
We hypothesized that basal UCP3 protein expression levels would be elevated in the skeletal muscles of
the OZR compared to the lean zucker rats (LZR). In addition, because aerobic exercise training has been
shown to elevate the ability of skeletal muscle to metabolize lipids, we also hypothesized that aerobic
exercise training would decreased UCP3 protein expression in the skeletal muscles, and that this decrease
would be more pronounced in the skeletal muscles of the OZR. METHODS: OZR and LZR animals
were aerobically trained on a motorized treadmill for 55 minutes a day 5 days per week for 9 weeks.
UCP3 and oxidative enzymes were measured in the plantaris, gastrocnemius, and soleus muscles of the
animals. RESULTS: Basal UCP3 protein expression was found to be elevated 8-fold in the plantaris
muscles and 3-fold in the gastrocnemius muscles of the OZR compared to the LZR (p < 0.05). However,
there was no difference in UCP3 protein expression in the soleus muscles of the OZR compared to the
LZR (p = 0.34). Furthermore, aerobic exercise training did not significantly alter UCP3 protein
expression in the soleus, plantaris, or gastrocnemius muscles of the LZR; however UCP3 protein
expression levels decreased in the trained soleus and gastrocnemius muscles compared with controls.
CONCLUSIONS: The decrease in UCP3 with aerobic exercise training was most notable in the soleus of
the OZR. These data demonstrate that there are muscle specific effects of obesity and aerobic exercise
training on UCP3 protein expression levels.

Key words: CITRATE SYNTHASE, AEROBIC TRAINING, UNCOUPLING PROTEIN 3,
METABOLIC SYNDROME
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INTRODUCTION

Paragraph number 1. Uncoupling proteins are a family of mitochondrial inner membrane proteins,
which are believed to be involved in the regulation of energy expenditure. Uncoupling protein 1 (UCP1),
which is highly expressed in brown adipose tissue, has been clearly demonstrated to contribute to
thermogenesis [see reviewed (1). Uncoupling protein 3 (UCP3) is a member of the uncoupling protein
family that is highly expressed in skeletal muscle, and shares a ~60 homology to UCP1 (2). Although
UCP3 was originally believed to have a similar function to UCP1, based on its homology, it has been
established that UCP3 does not contribute to thermogenics or muscle proton leak [reviewed (3)]. A
potential function of UCP3 is that UCP3 may serve as a mitochondrial mediator of fatty acid metabolism
in the muscle It has been demonstrated that elevated circulating free fatty increases muscle UCP3 protein
expression levels in both in human and animal models (4-7), perhaps as an attempt to prevent lipidinduced oxidative damage to muscle mitochondria. Furthermore, when free fatty acid levels are elevated
during exercise there is an increase in UCP3 mRNA (8;9), and protein levels (10;11). On the other hand it
has been proposed that UCP3 may play a protective role against reactive oxygen species (ROS)
production (3;12;13), although this may be directly related to preventing lipid peroxidation (3).
Nevertheless, these data support the hypothesis that UCP3 is actively involved in free fatty acid
metabolism and therefore, the increase in UCP3 with acute exercise may be a means of mitochondria
protection under conditions of high fatty acids.

Paragraph number 2. In contrast to an acute bout of exercise, long-term aerobic exercise training may
produce the opposite effect on UCP3. Boss et al. reported that 8-weeks of treadmill running resulted in a
76% and 59% decrease in UCP3 mRNA in the tibialis anterior and soleus muscles of rats, respectively
(14), however, it is not known if the UCP3 protein levels were also decreased in this study. Similarly, in a
cross-sectional study, the UCP3 protein levels in quadriceps muscles of endurance-trained men were
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significantly lower when compared with untrained controls (15). Furthermore, Fernstrom and colleagues
(16) demonstrated that long-term aerobic training decreased UCP3 protein expression when normalized to
mitochondrial activity. Combine these data provide evidence that the increase UCP3 protein expression is
transient and that the UCP3 contributes to the acute adaptation to exercise (3).

However, to our

knowledge no study has examined the response of UCP3 protein expression levels to aerobic exercise
training in primarily glycolytic muscles, like the plantaris, vs. a primarily oxidative muscle like the
soleus.

Paragraph number 3. In addition to aerobic training, obesity, or any situation in which free fatty
acid levels were elevated, could alter UCP3 protein expression levels. For example, in rodent models a
high fat diet induced an increase in UCP3 protein expression in some (5;6;17), although not all studies
(18). For example, Chou and colleagues (6) determined that high fat diet (60% of energy from fat, for 4
weeks) increased UCP3 content along with plasma free fatty acid levels.

The obese Zucker (fa/fa) rat

(OZR) is rodent model consistently used in the literature as a model of severe obesity. The OZR have a
dysfunctional leptin receptor and therefore do not properly regulate their food intake (19). This results in
rapid and severe obesity, skeletal muscle insulin resistance, hyperglycemia, and high levels of free fatty
acids (20-22). Because of the high levels of plasma free fatty acids in the OZR it would be expected that
the OZR would have increased UCP3 expression, compared to the lean zucker rat (LZR), similar to the
high fat feeding model. However, previous work in the OZR has demonstrated that there is a decrease in
the UCP3 mRNA expression in the soleus muscle compared to the LZR (23) whereas, in a separate study
there was a significant increase in UCP3 protein expression in the quadriceps of the OZR compared to the
LZR (20). However, neither of these studies examined UCP3 expression in multiple types of muscles
(glycolytic or oxidative muscles). This is important because it is possible that the response of UCP3 to
treatment (e.g., diet or exercise) could be muscle phenotype specific and vary between glycolytic
compared to oxidative muscles (4;24-27). For example, Schrauwen and colleagues (24) demonstrated
that the regulation of UCP3 protein expression, in response to a high fat diet, was related to muscle fiber
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type in healthy humans. Similarly, both glycolytic and oxidative skeletal muscles of the OZR are
exposed to significantly higher levels of free fatty acids compared to the LZR (28). However, the
regulation of UCP3 to either the severe obesity, as observed in the OZR, or aerobic exercise could be
different depending on the muscle being examined. Together, these data demonstrate the need for further
study of the interaction between obesity, aerobic exercise training, and UCP3 protein expression levels in
both oxidative and glycolytic skeletal muscles.
Paragraph number 4. It has been demonstrated that aerobic exercise training increases the proteins
responsible for fatty acids oxidation (29). Increased metabolism of fatty acids would reduce the need for
UCP3 to remove non-metabolized fatty acids, which in turn could allow for the decrease in UCP3 protein
expression in skeletal muscle with aerobic exercise training (3;8;14;30). However, there is a scarcity of
data concerning the interactions of obesity, muscle oxidative capacity, and exercise on UCP3 content in
skeletal muscle. Therefore, the purposes of this study were three-fold: (i) first to determine if basal UCP3
is elevated in both fast and slow hindlimb muscles of OZR compared to LZR; (ii) secondly, to determine
whether aerobic exercise alters the content of UCP3 in the skeletal muscles of the OZR differently from
the LZR; (iii) third, to determine if changes in UCP3 protein expression are dependent on the oxidative
capacity of the muscle being examined.
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METHODS

Paragraph number 5. Animals. An equal number of 6 week old male OZR and LZR rats (Harlan,
Indianapolis, IN) were randomly assigned to control (C, n = 16) or training (ET, n = 16) groups. Animals
were housed in pathogen-free conditions, two per cage, at 20-22°C with a reversed 12:12-h light-dark
cycle, and fed rat chow and water ad libitum throughout the study period. All animal procedures were
conducted in accordance with institutional guidelines, and ethical approval was obtained from the Animal
Care and Use Committee at the West Virginia University.

Paragraph number 6. Training protocol. Animals were trained by running on a level motorized rodent
treadmill (Columbus Instruments, Columbus, OH) 5 days weekly for 9 weeks. During the first 4 wk, the
speed of the treadmill and duration of the training sessions were gradually increased from a speed of
10 m/min for 10 min to a running speed of 20 m/min for the OZR and 24 m/min for the LZR. Different
speeds were used to compensate for the increased intensity of exercise for the OZR due to increased body
weight compared to LZR. Our pilot work suggested that the difference in body weight would vary around
40% and we used an estimation based on the formula of “work=1/2 mass * velocity squared
(W=1/2m*V2)” and the estimated final weights of 500 grams for the OZR and 350 grams for the LZR.
This calculation estimates that at 20 and 24 m/min for the OZR and LZR, respectively, they would have
an estimated final work output of 0.028 joules. Furthermore, our pilot data demonstrated that these
intensities would be able to be reliably maintained by the OZR and LZR, respectively, with minimal
motivation by the investigators. Additionally, as demonstrated by the mitochondrial proteins examined in
this study we saw similar increases in the trained groups of both the OZR and LZR. During weeks
5 through 9, a 5-min warm-up session at a speed of 15 m/min was followed by the 55-min training
session. During the training sessions, mild electrical shock stimulation was applied, if necessary, to
maintain the running motivation. Animals assigned to the control group were handled daily and exposed
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to the noise of the running treadmill by placing their cages next to the treadmill during the exercise
session.

Paragraph number 7. Forty eight hours after the last training session and an overnight fast (~16 hours)
animals were anesthetized with isoflurane and euthanized via cardiac puncture at which time the soleus,
plantaris, and gastrocnemius muscles were quickly removed, frozen immediately in liquid nitrogen and
stored at -80°C until further analysis. These muscles were chosen to examine changes in UCP3 in
response to aerobic training in the oxidative (soleus), glycolytic, (plantaris), and mixed oxidative and
glycolic (gastrocnemius) muscles. Although it has been demonstrated that there is a reduction in percent
of total fiber area occupied by the glycolytic fibers in the OZR compared to the LZR, the relative

percentage of the glycolytic to oxidative fibers remained constant (31).

Torgan et al.

demonstrated that the OZR has ~77% type I fibers in the soleus muscle compared to the LZR
(~83%), with no difference in fiber type percentages in the plantaris muscle between the OZR
and LZR (~10% type I, ~68% type IIa, and ~22% IIb).

Paragraph number 8. Western Blot analyses. Protein extracts were obtained from hindlimb muscles as
routinely performed in our lab (32). The protein contents of the solublized extracts were quantified in
duplicate by using bicinchoninic acid reagents (Pierce, Rockford, IL, USA) and bovine serum albumin
(BSA) standards. 40 µg of soluble protein was boiled for 4 min at 100°C in Laemmli buffer and loaded
on each lane of a 12% polyacrylamide gel.

The proteins were separated by NuPage Bis-Tris gel

(NP0303, Invitrogen, CA, USA) with NuPage Running Buffer MES-SDS (NP0002; Invitrogen, CA,
USA) for 1.5 hours at 20°C, and molecular weight was confirmed with SeeBlue2®Plus2 (LC5925,
Invitrogen, CA, USA). The gels were blotted to nitrocellulose membranes (Bio-Rad, Hercules, CA,
USA) and stained with Ponceau S red (Sigma Chemical Co, St Louis, MO, USA) to confirm equal
loading and transferring of proteins to the membrane in each lane.
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Paragraph number 9. The membranes were then blocked in 4% non-fat milk in Tris buffered
saline with 0.05% Tween 20 (TBS-T) and probed with an UCP3 antibody (AB3046; Chemicon, CA,
USA), cytochrome c oxidase subunit I (COX I; Invitrogen, CA, USA) or beta-tubulin antibody (Abcam,
MA, USA). Isolated skeletal muscle mitochondrial protein and rat liver homogenate were used as
positive and negative controls, respectively, for UCP3. Secondary antibodies were conjugated to
horseradish peroxidase (HRP) (Chemicon) and the signals were developed by chemiluminescence (Pierce,
Rockford, IL, USA). The signals were visualized by exposing the membranes to X-ray films (BioMax
MS-1, Eastman Kodak, Rochester, NY, USA), and digital records of the films were captured with a
Kodak 290 camera. The resulting bands were quantified as optical density (OD) x band area by a onedimensional (1-D) image analysis system (Eastman Kodak, Rochester, NY, USA) and expressed in
arbitrary units normalized to the OD of beta-tubulin. The sizes of the proteins were verified by using
standard molecular-weight markers (Bio-Rad, Hercules, CA, USA).

Paragraph number 10. Citrate synthase activity assay. Approximately 20 mg of soleus muscle samples
were homogenized on ice in 0.1 M Tris buffer containing 0.1% Triton X-100, pH 8.35. Citrate synthase
(CS) activity was determined spectrophotometrically according to the method of Srere et al (33) and as
conducted routinely in our laboratory. The homogenates were frozen under liquid nitrogen and thawed
four times to disrupt the mitochondria in order to release the CS. The assay system was in a total volume
of 200 µl: 100 mM Tris buffer (pH 8.35), 5 mM 5,5-dithiobis (2-nitrobenzoate) (DTNB), 22.5 mM acetylCoA, 25 mM oxaloacetate (OAA), and 4 μl of homogenate. The rate in change in color was monitored at
a wavelength of 405 nm sec intervals for a period of 3 min by using a Dynex MRX plate reader controlled
through PC software (revelation, Dynatech Laboratories, CA, USA). All measurements were performed
in duplicate, in the same setting at 20-22°C. The solublized protein extracts of the homogenates were
quantified in duplicate by using bicinchoninic acid reagents (Pierce, Rockford, IL, USA) and BSA
standards. The CS activity was normalized to the total protein expression and was reported as nanomoles
per milligram protein per minute.
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Paragraph number 11. Statistical analyses. Results are presented as means ± SE. A One-way ANOVA
was used to examine differences across groups. Tukey's Post hoc tests were used to determine differences
between the means. Significance was set at P < 0.05.
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RESULTS

Paragraph number 12. Characterization of animals. At the start of this study the OZR had significantly
elevated body weights compared to the LZR (224.6 ± 16.6 vs. 171.9 ± 14.9 g, p < 0.05). No differences
in starting body weight were observed between control and trained animals within phenotype. After
training, the animals were 15-16 weeks old. Training significantly lowered the body weights of OZR
(658 ± 18 vs. 502 ±21 g, p < 0.05) but not LZR (358 ± 11 vs. 360 ±16 g) animals as previously reported
(22).

Paragraph number 13. UCP3 protein levels. The effects of obesity and/or exercise on the protein
concentrations of UCP3 in the hindlimb muscles were dependent on the muscle being examined. In the
fast contracting plantaris and medial gastrocnemius muscles, there was an 8-fold and 3-fold increase,
respectively, in the basal level of UCP3 in the OZR compared to the LZR (Figure 1A & 1B). However,
this difference was not observed in the soleus muscles of the OZR compared to the LZR (Figure 1C).
Exercise had no effect on UCP3 concentration in either the fast contracting plantaris or medial
gastrocnemius muscles (Figure 1A & 1B). Additionally, aerobic exercise had no effect on the UCP3
content in the slow contracting soleus muscles of the LZR. Conversely, in the soleus muscles of the OZR
there was a 67% decrease with aerobic exercise (Figure 1C).

Paragraph number 14. COX I protein levels. COX I is an inner mitochondrial membrane–
bound enzyme which has a role in the electron transport chain. COX I was examined as a marker for
mitochondrial content (11). This measure was important to determine if the training protocol was
effective in increasing the mitochondrial protein fraction, and secondly to help determine whether
changes in UCP3 expression were consistent with or independent from mitochondrial biogenesis. COX I
protein expression increased in both the plantaris and soleus muscles with training (Figure 2A).
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Furthermore, UCP3 normalized to COX I protein expression (UCP3/COX I) was also examined (Figure
2B). UCP3/COX I was reduced in both the medial gastrocnemius (42%) and the soleus (59%) muscles of
the LZR animals, but there was no change in the plantaris muscles. In the OZR, UCP3/COX I was
reduced in the plantaris and soleus muscles, by 30% and 81% respectively, with no change in the medial
gastrocnemius muscles.

Paragraph number 15. Citrate Synthase activity. To further verify that the training protocol was
effective, CS activity, shown in figure 3, was measured biochemically in the soleus muscles of all trained
and control animals. Similarly, to past studies from our lab (32), CS activities increased by ~30% in
soleus muscles in trained muscles from both the OZR and LZR animals.
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DISCUSSION

Paragraph number 16. The primary novel findings from this study are that UCP3 protein
expression is affected by obesity and muscle phenotype, in the OZR. In this study we show a significantly
greater basal UCP3 protein expression in the fast contracting glycolytic muscles of the hindlimb
(gastrocnemius and plantaris) of the OZR compared to the LZR; however, there was no affect of obesity
on UCP3 protein expression in the slow contracting oxidative soleus muscles.

Paragraph number 17. Previous research has shown that the OZR has significantly elevated palmitate
(the most common free fatty acids found in the body) uptake per gram of muscle tissue as compared with
LZR (28). This increase in exposure to free fatty acids may partially explain the increased UCP3 protein
expression in the plantaris and gastrocnemius muscles that we observed in the current study. However, it
remains unclear why UCP3 protein expression is not different in the soleus muscles of the LZR and the
OZR. One possible explanation is that UCP3 expression may be determined in part by the manner in
which fatty acids are stored in glycolytic and aerobic muscles. For example, Turcotte and colleagues (28)
reported that glycolytic muscles in the OZR have elevated diacylglycerol synthesis compared to the LZR,
whereas the oxidative muscle have elevated triglyceride synthesis compared to the LZR. However, the
interactions between UCP3 and di- or triglycerides have not been elucidated. Another possibility is that
the mitochondria in highly oxidative soleus muscles have sufficient UCP3 to provide stabilization to the
mitochondria under conditions of high fatty acids, whereas, mitochondria in fast contacting muscles have
less UCP3 and respond to the exposure of fatty acids by elevating the expression of UCP3.

Paragraph number 18. In this study we report that 9 weeks of aerobic exercise training resulted in
decreases in UCP3 protein expression, and UCP3 expression normalized to mitochondrial protein
expression, in the hindlimb muscles. It is important to note that nine weeks of aerobic training at
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this intensity and duration were sufficient to increase the mitochondrial protein expression (COX I) in the
plantaris and soleus muscles of both the LZR and OZR, and that these increases were not different
between groups. This would indicate that the animals had achieved adaptations to the aerobic exercise,
and that the different training speeds were appropriate to illicit similar increases in mitochondrial protein
expression in both the LZR and OZR. Furthermore, the soleus muscles of both the LZR and the OZR had
significant increases in mitochondrial protein (COX I) and mitochondrial activity (CS activity) with a
relative decrease in UCP3 protein expression. It has been proposed that aerobic training increases
metabolic efficiency, which decreases the expression of UCP3 in skeletal muscle (14;34;35) perhaps
because mitochondria are stabilized to prevent oxidative damage by elevation of other oxidative enzymes
(e.g., MnSOD, GPx, GSH/GSSG) in muscle or blood (36-38). Recent data provide additional evidence
that UCP3 may provide a protective role for mitochondria, because the enhanced H2O2 emitting potential
of mitochondria is returned to resting levels when UCP3 is increased in vivo (39). Furthermore, Hellsten
and colleagues (40) have recently shown that antioxidant supplementation increased UCP3 expression
levels in muscle after acute exercise and this suggests a clear linkage of UCP3 and adaptations to
oxidative stress. In addition, to regulation by oxidative stress, the decrease in UCP3 levels after aerobic
training in the current study could also be indicative of adaptations in muscle mitochondria to exercise
because UCP3 contributes to the rate of state 4 respiration in skeletal muscle mitochondria (41). In
support of this hypothesis, other studies which have examined chronic aerobic exercise training models,
have also demonstrated a decrease in UCP3 expression with training (14;15).

Paragraph number 19. Our findings, are in agreement with data from previous studies which found that
protein expression of UCP3 does not increase in parallel with training-induced mitochondrial biogenesis
(14;16;42). However this is contrary to the findings of others who reported increased UCP3 protein
concentration (11) or mRNA expression (11;35) during 10 or 14 days, respectively, of aerobic training.
We cannot rule out the possibility that there was an initial increase in UCP3 protein levels during the first
2-weeks of exercise training, but if this occurred, then this was a transient increase. This possibility,
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would explain why Jones and colleagues (11) found a parallel increase in UCP3 concentration and
mitochondrial biogenesis. Our data suggest that such acute increases in UCP3 would likely be transient,
since decreased UCP3 protein concentration and mRNA expression are reported both with aerobic
training (14;16) and in aerobic trained cross-sectional studies (4;15;42). It is possible that if UCP3
protein concentration was examined within 24 hours of the last training bout an increased protein
concentration would have been observed as in aforementioned studies.

Paragraph number 20. A novel finding of this study was that the reduction in UCP3 protein
expression with aerobic exercise training was more evident in the soleus muscle of the OZR than in the
soleus of the LZR, or in either of the glycolytic muscles. It has been demonstrated that muscles higher in
type I fibers (like the soleus) are more susceptible to exercise induced changes in UCP3 content (27).
This may partially explain why the soleus muscles, which is composed of ~80% type I fibers (43;44),
demonstrated the most notable decline in UCP3 protein expression. Although there are significant
differences in skeletal muscle fiber type percentages in muscles of the OZR compared to the LZR, the
general trend in fiber type distribution remains similar to other rodent models, with the soleus muscle
being composed primarily of type I fibers (~80%), the plantaris with predominately type IIa fibers
(~60%), and the gastrocnemius representing both type I and type II fibers (29;43;44). Furthermore, it
was confirmed in this study that among the muscles examined UCP3 protein expression followed a
similar pattern in the OZR and LZR with it being lowest in the soleus muscles and no difference between
the plantaris and gastrocnemius muscles.

Paragraph number 21. OZR animals were heavier than LZR animals, so if the animals were to
run at the same pace, the muscles of the OZR animals would have a greater total workload than the LZR.
Although we attempted to match training intensities by allowing the LZR to run at a faster pace than the
OZR, we cannot completely rule out the possibility that potential differences in the training intensity may
explain, at least in part, why the changes in normalized UCP3 protein expression were different between
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phenotypes. Nevertheless, it is apparent that both animal phenotypes increased mitochondrial protein
expression in the plantaris and soleus muscles similarly, but that decreases in normalized UCP3 protein
expression were more pronounced in the OZR.

Paragraph number 22. In conclusion, this study demonstrated that there is an interaction effect
of muscle type (glycolytic or aerobic) and obesity in regards to the effect on UCP3 protein expression.
Although the OZR has a significantly elevated UCP3 protein expression in the glycolytic muscles
(plantaris) there was no difference in the aerobic muscles (soleus) between the two animal groups. On the
other hand, aerobic exercise had a similar effect on lowering the protein expression of UCP3 relative to
the mitochondrial protein COX I. These data indicate that although there are differences in between the
LZR and OZR, aerobic exercise affects them similarly.
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FIGURE LEGENDS
Figure 1

UCP3 content in hindlimb muscles. The UCP3 protein expression was examined by
Western immunoblots in the plantaris (A), medial gastrocnemius (B), and soleus muscles
(C). Male obese Zucker (OZR-ET), n=8) and lean Zucker (LZR-ET, n=8) were
endurance trained (ET) on a motorized treadmill for 12 weeks. Control (LZR, n = 8;
OZR, n=8) LZR and OZR animals were exposed to the similar environment (positioned
next to the treadmill) but were not exercised. The insets show representative Western
blots for UCP3 and β-tubulin. β-tubulin was used as the loading control for each sample.
The data are expressed in arbitrary units with UCP3 normalized to the β-tubulin content
of each lane, and presented as means ± SE. *P < 0.05, data from OZR animals was
significant different from the LZR animals. **P < 0.05, significantly different from all
other groups.

The main effects of obesity (OZR or LZR) and exercise interaction

(obesity x exercise) in these animals were analyzed by a 2 × 2 ANOVA. Data are
presented as means ± SE.

Figure 2

The effects of endurance training on COX I protein expression. (A) The COX I
protein expression was examined by immunoblot analysis. We recorded a band at ~37
kDa as known in previous studies (45). The insets show representative Western blots for
COX I and β-tubulin, which was used as the loading control for each sample. The data
are expressed in arbitrary units with COX I normalized to the β-tubulin content of each
lane. (B) UCP3 protein expression normalized to COX I protein expression. Data are
presented as means ± SE. *P < 0.05, data significantly different from the LZR control
animals. **P < 0.05, significantly different from control OZR. The main effects of
obesity (OZR or LZR) and exercise interaction (obesity x exercise) in these animals were
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analyzed by a 2 × 2 ANOVA. Data are presented as means ± SE. Other abbreviations are
identical to Figure 1.

Figure 3

The effects of endurance training on citrate synthase (CS) activity in soleus muscles.
CS activity was determined in the soleus muscle of control and aerobically trained LZR
and OZR rats. CS activity is normalized to the total protein expression of the sample used
in the assay. Data are normalized to the protein expression of the sample and expressed as
units • mg prot-1 • min-1. *P < 0.05, data significantly different from the LZR control
animals. **P < 0.05, significantly different from control OZR. Data are presented as
means ± SE. Other abbreviations are identical to Figure 1.
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IN VITRO METHODS
C2C12 Culture.
C2C12 myoblasts were purchased from American Type Culture Collection (ATCC,
Manassas, VA). The cells were cultured in 100 mm polystyrene culture dishes in Dulbecco
Modified Eagle’s Medium (Invitrogen, USA) supplemented with 10% FBS and 1% antibiotic
antimycotic mixture and passaged in 0.25% trypsin. The cells were maintained in a humidified
incubator under an atmosphere of 5% CO2 at 37ºC. Fresh medium was supplied every 24-36
hours unless otherwise noted.

Differentiation.
For differentiation into myotubes, the myoblasts were grown to confluency and transferred to
DMEM containing ITS liquid media (Sigma-Aldrich, St. Louis, MO). Myotubes were used for
experiments following 4 days of differentiation, unless otherwise noted. All experiments were
performed in triplicate.

Free Fatty Acid Treatment.
Palmitate (Sigma Chemicals; St. Louis, MO) was administered to cells as described by Chavez
and Summers (46;47) with dodecanoic acid (laurate) used as a short chain free fatty acid (FFA)
to differentiate the effects of FFAs alone and FFAs which interfere with Akt signaling. Briefly,
palmitate was dissolved in ethanol and diluted in DMEM containing 2% BSA. C2C12 myotubes
were incubated with the FFAs (0.75mM final concentration) in 1% FBS–DMEM for 16 h,
washed with DHANKS, and then incubated with the FFA in serum free DMEM for 2 hours. 1%
FBS was reintroduced to the media 10 minutes prior to collection, except where indicated.
C2C12 myoblast were incubated with FFAs (0.25mM final concentration) in 10% FBS for 12-24
hours and harvested immediately, except where indicated. Control experiments were performed
with 2% BSA in the absence of FFAs.

Myoblast proliferation.
The first experiment performed was to determine if palmitate treatment inhibited myoblast
proliferation. For this experiment C2C12 myoblasts were suspended in trypsin, centrifuged at
20ºC for 5 minutes at 1500 rpm and then resuspended in PBS. Next 10 µM carboxyfluorescein
diacetate, succinimidyl ester (CFSE) was added to the cells and then the staining was
immediately quenched with the addition of an equal volume of 10% FBS. An aliquot was fixed
in 1% paraformaldehyde, to determine initial staining intensity. The cells were then plated into
35mm plates in 10% FBS and allowed to grow for 24 hours. At this point the myoblasts were
treated with palmitate, laurate, Akt-inhibitor (124005, Calbiochem, Germany) or BSA only and
allowed to grow for an additional 24 hours. Next, the myoblasts were washed twice with PBS,
harvested in 0.25% trypsin, and fixed with 1% paraformaldehyde, and examined using the
FACSCaliburTM Flow Cytometer.
An additional proliferation assay was performed in a separated experiment in which the
C2C12 myoblasts were grown to ~50 percent confluency, treated with or without FFAs, pulsed
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for 20 min with 30 µg/ml BrdU (550891, BD Biosciences Pharmingen, USA), harvested in
trypsin, and fixed in ice cold 70% EOTH for 24 hours. The myoblast were then resuspended in
0.1% triton-X/0.1 M HCL for 1 min, centrifuged at 2000 rpm for 5 min, then resuspended in
DNA Denaturing Buffer (0.15 µM NaCl, 15 µM Trissodium citrate dihydrate) at 95°C for 5 min,
followed by incubation at 4ºC for 5 min, and centrifuged 2000 rpm 5 min. Next the pellet was
washed in 1% BSA in PBS and then resuspended in Mouse anti-BrdU (1:50; 555627; BD
Pharmingen™, USA) for 30 min at room temperature. Next the cell were washed twice in PBS
and then incubated with Anti-mouse Alexa-488 secondary antibody (1:400; A11029; Invitrogen,
USA). Lastly, the myoblasts were wash twice with PBS and then resuspended in Propidium
Iodide (10 µg/ml; P3566, Invitrogen, USA), RNAse (100 µg/ml; 10109169001; Roche, USA) in
PBS and analyzed a FACSCaliburTM Flow Cytometer.

Flow Cytometry Analysis.
The cells were transferred to 5 ml polstytrene round bottom tubes for data acquisition and
analysis on a FACSCaliburTM Flow Cytometer using CellQuest Pro software (BD Biosciences).
All data are represented as mean fluorescence intensity (MFI). Additional cell cycle modeling
was performed using Modfit LT software (Verity Software house, Inc).

siRNA transfection.
The myotubes were transfected with scrambled, nonspecific siRNA without mammalian
homology, or Bax siRNA (Santa Cruz Biotechnology, Santa Cruz, CA) using Lipofectamine
2000 (Invitrogen Carlsbad, CA). Individual siRNAs (80 pmols/transfection) were transfected
using Lipofectamine in serum-free DMEM for 6 hours. A 2x concentration (2%FBS, 4% BSA,
and 1.25 mM of palmitate) of media was then added to each well and the samples were incubated
for an additional 12 hours.
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IN VIVO MODELS
Animal Care.
Obese and Lean zucker rats were purchased from Harlan labs (Harlan, Indianapolis, IN).
Animals were housed in pathogen-free conditions, at 20-22°C, and fed rat chow and water ad
libitum throughout the study period. The animal care standards were followed by adhering to the
recommendations for the care of laboratory animals, as advocated by the American Association
for Accreditation of Laboratory Animal Care, which fully conformed to the Animal Welfare Act
of the US Department of Health and Human Services. All animal procedures were conducted in
accordance with institutional guidelines and ethical approval was obtained from the Animal Care
and Use Committee at the West Virginia University prior to carrying out tests.

Denervation procedure.
To achieve compensatory hypertrophy, synergist denervation was employed. Briefly, the
animals were placed under a general anesthesia using 2% isoflurane, and after cessation of reflex
activity, the medial and lateral branches of the tibial nerve that innervate the plantar flexor
muscles (i.e. gastrocnemius and soleus) were cut, and the cut nerve ends were sutured into the
biceps femoris muscle to ensure that the nerve stumps did not reinnervate the gastrocnemius
muscle. Care was taken to avoid any damage to the nerves, blood vessels and connective tissues.
Innervation to the plantaris and the deep toe flexor muscles were left intact so that the animals
ambulated normally around the cage after the surgical denervation. Following the surgery, the
hamstring muscle layers were closed with reabsorbable suture, and the skin incisions were closed
with wound clips. The incision sites were covered with an antibacterial cream to prevent
infection. This resulted in removing the enervation to both heads of the gastrocnemius muscle
and soleus muscles and placing a compensatory load on the plantaris muscle according to our
previously published methods (48).
The contralateral limb received a sham surgery in which the branches of the tibial nerve
were examined but not severed, and this served as an internal control for each animal. All
procedures were performed under aseptic conditions. The animals recovered quickly and were
alert and walking within ~45 min after surgery. Loading occurred for 7 or 21 days. In addition to
placing a compensatory load on the plantaris muscle withdrawal of innervations to the medial
gastrocnemius results in an highly-favorable apoptotic environment for this muscle (49).

BrdU implantation.
A time-released bromodeoxyuridine (BrdU) pellet (21-day release, 0.22 µg BrdU·g body mass–
1·day–1; Innovative Research, Sarasota, FL) was placed subcutaneously on the dorsum. BrdU is
a thymidine analog and is incorporated in nuclei during DNA synthesis. Therefore, it was used to
identify activated satellite cells/muscle precursor cells during the 7- or 21-day period of muscle
loading-induced hypertrophy.

Treadmill training protocol.
Animals were trained by running on a level motorized rodent treadmill (Columbus Instruments,
Columbus, OH) 5 days weekly for 9 weeks. During the first 4 wk, the speed of the treadmill and
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duration of the training sessions were gradually increased from a speed of 10 m/min for 10 min
to a running speed of 20 m/min for the OZR and 24 m/min for the LZR. Different speeds were
used to compensate for the increased intensity of exercise for the OZR due to increased body
weight compared to LZR. Our pilot work suggested that the difference in body weight would
vary around 40% and we used an estimation based on the formula of “work=1/2 mass * velocity
squared (W=1/2m*V2)” and the estimated final weights of 500 grams for the OZR and 350
grams for the LZR. This calculation estimates that at 20 and 24 m/min for the OZR and LZR,
respectively, they would have an estimated final work output of 0.028 joules. Furthermore, our
pilot data demonstrated that these intensities would be able to be reliably maintained by the OZR
and LZR, respectively, with minimal motivation by the investigators. Additionally, as
demonstrated by the mitochondrial proteins examined in this study we saw similar increases in
the trained groups of both the OZR and LZR. During weeks 5 through 9, a 5-min warm-up
session at a speed of 15 m/min was followed by the 55-min training session. During the training
sessions, mild electrical shock stimulation was applied, if necessary, to maintain the running
motivation. Animals assigned to the control group were handled daily and exposed to the noise
of the running treadmill by placing their cages next to the treadmill during the exercise session.

Tissue Collection.
Animals were anaesthetized with ketamine hydrochloride, (9 mg x 100 g body weight–1) and
xylazine hydrochloride (1 mg x 100 g body weight–1), I.P. and the hindlimb muscles from each
limb were removed and frozen in isopentane, cooled to the temperature of liquid nitrogen, and
stored at -80°C until further analysis. Additionally, a mid-belly section of each muscle was fixed
in 10% formalin and was embedded in paraffin.
For examination of the muscles that underwent compensatory loading or denervation.
The hindlimb muscles were collected seven (n=6 LZR-7 and n=6 OZR-7) and 21 days (n=6
LZR-21 and n=6 OZR-21) after the surgical denervation. The animals were all 12 weeks old at
time of tissue collection. The hindlimb muscles from the treadmill trained animals were harvested forty
eight hours after the last training session and an overnight fast (~16 hours).
These muscles were chosen to examine changes in in the oxidative (soleus), glycolytic, (plantaris),
and mixed oxidative and glycolic (gastrocnemius) muscles. Although it has been demonstrated that there
is a reduction in percent of total fiber area occupied by the glycolytic fibers in the OZR compared to

the LZR, the relative percentage of the glycolytic to oxidative fibers remained constant (31).
Torgan et al. demonstrated that the OZR has ~77% type I fibers in the soleus muscle compared
to the LZR (~83%), with no difference in fiber type percentages in the plantaris muscle between
the OZR and LZR (~10% type I, ~68% type IIa, and ~22% IIb).

PROTEIN ANALYSIS.
Immunoblot analysis
The protein contents of the solublized extracts were quantified in duplicate by using
bicinchoninic acid reagents (Pierce, Rockford, IL, USA) and bovine serum albumin (BSA)
standards. 60 µg of soluble protein was boiled for 4 min at 100°C in Laemmli buffer and loaded
on each lane of a 12% polyacrylamide gel. The proteins were separated by routine SDS-PAGE
for 1.5 hours at 20°C. The gels were blotted to nitrocellulose membranes (Bio-Rad, Hercules,
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CA, USA) and stained with Ponceau S red (Sigma Chemical Co, St Louis, MO, USA) to confirm
equal loading and transferring of proteins to the membrane in each lane.
The membranes were then blocked in 5% non-fat milk in Tris buffered saline with 0.05% Tween
20 (TBS-T) and then probed with appropriate primary antibody (see table 1). Goat anti-rabbit
secondary antibodies were conjugated to horseradish peroxidase (HRP) (Chemicon, CA, USA)
and the signals were developed by chemiluminescence (Pierce, Rockford, IL, USA). The signals
were visualized by exposing the membranes to X-ray films (BioMax MS-1, Eastman Kodak,
Rochester, NY, USA), and digital records of the films were captured with a Kodak 290 camera.
The resulting bands were quantified as optical density (OD) x band area by a one-dimensional
(1-D) image analysis system (Eastman Kodak, Rochester, NY, USA) and expressed in arbitrary
units nits normalized to ß-Tublin. The sizes of the proteins were verified by using standard
molecular-weight markers (Bio-Rad, Hercules, CA, USA). To reduce the day-to-day variability
between blots all comparisons were performed on samples run on the same membrane.
Protein Isolation
Total Protein homogenates of whole muscle sections were prepared in lysis buffer (20 mM Tris
pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% Sodium Deoxycholate, 1 mM EDTA, 0.1%
SDS) with the addition of Protease inhibitor cocktail (PIC; Sigma). Separate mitochondrial and
mitochondria free protein fractions were also prepared according to methods as previously
performed in our lab (50). Briefly, samples were homogenized in mitochondrial isolation buffer
(20 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM
dithiothreitol, 250 mM sucrose) with protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO,
USA). The homogenates were centrifuged at 800 x g to remove nuclei and cell debris followed
by centrifugation at 16,000 x g for 20 min at 4°C to pellet the mitochondria. The supernatants
were used as mitochondria-free cystosol. The mitochondrial pellet was washed twice then
resuspended in total protein lysis buffer for analysis of Bax associated with the mitochondrial
membrane.

Total protein homogenates of C2C12 myoblast and Myotubes were obtained by washing 3
times in ice-cold PBS then the cells were lysed in 1x SDS sample buffer (50 mM Tris-HCl, pH
6.8, 2% SDS, 6% glycerol, 1% β-mercaptolethanol, 0.02% bromophenol blue) was added
directly to the myotubes. 2x SDS lysis buffer was added to an equal volume of the subcellular
fractions obtained below. Samples were then lysed with a 25 gauge needle and boiled for 5 min
at 100°C and separated on a 4-12% gradient polyacrylamide gel (Invitrogen, USA). Gels were
blotted to nitrocellulose membranes (Bio-Rad, Hercules, CA) and stained with Ponceau red
(Sigma Chemical Co, St Louis, MO, USA) to confirm equal loading.

Nuclear and cytoplasmic protein extracts.
The nuclear and cytoplasmic protein extracts were obtained using the method described by
Rothermel et al. (51) and performed routinely in our lab. For in vitro experiments cells were
washed 3 times in ice-cold phosphate buffered saline (PBS) then incubated in lysis buffer (10
mM NaCl, 1.5 mM MgCl2, 20 mM HEPES, pH 7.4, 20% glycerol, 0.1% Triton X-100, and 1
mM dithiothreitol) for 5 minutes at 4ºC. The cells were gently homogenized in a small glass
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homogenizer with Teflon pestle. For the in vivo experiments muscle samples were homogenized
in 1:10 ice-cold lysis buffer (10 mM NaCl, 1.5 mM MgCl2, 20mM HEPES at pH 7.4, 20%
glycerol, 0.1% Triton X-100, and 1mM dithioreitol) with a mechanical homogenizer. Muscle
homogenates were transferred to 1.5ml Eppendorf tubes and centrifuged at 300 rpm for 5minutes at 4°C.
The homogenates were centrifuged at 1,000 rpm for 1 min at 4°C. The supernatants were
spun twice more at 2,000 RPM and the final supernant contained the cytoplasmic protein
fraction. The initial pellet contained the nuclear protein fraction. The nuclear pellet was washed
twice in lysis buffer and then resuspended in lysis buffer containing 0.6 M NaCl. The mixture
was incubated for 1 h at 4°C and centrifuged at 14,000 rpm for 15 min at 4°C. The supernatants
contained the nuclear protein fraction. A portion of the cytosolic extract (without addition of
protease inhibitors) was stored and used for fluorometric caspase activity assays, while protease
inhibitor cocktail (PIC, Sigma-Aldrich, St Louis, MO) was added to the nuclear and remaining
cytosolic portion for further analysis.

Mitochondrial Isolation.
For the isolation of the mitochondrial and nuclear fraction from the cytoplasmic protein fraction
the samples were incubated in ice-cold Mito-buffer (20 mM HEPES pH 7.5, 10 mM KCl, 1.5
mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol, 250 mM sucrose, and 0.1 mM
phenylmethylsulfonyl fluoride) for 15 minutes. The samples were homogenized by
homogenization in a small glass homogenizer with Teflon pestle. For the in vivo experiments the
samples were initially minced with scissors before homogenization. The homogenates were
centrifuged at 800 g to remove nuclei and cell debris and then centrifuged at 16,000 g for 20 min
at 4°C to pellet the mitochondria. The supernatant contained the mitochondrial-free cytosolic
protein fraction and this used for analysis.
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Table of immunoblot Antibodies
Protein

Product number

Total Akt
Akt1
Akt2
Myosin Heavy Chain
MyoD
Myogenin
Cyclin D
Cyclin B1
Phosph-Cyclin B1
p27
p21
p21
p53
Mn SOD
Cu/Zn SOD
COX I
Beta-tubulin
Smac/Diablo
AIF
UCP3
Bax
Bcl-2
BAD
FoxO3a
FoxO1
FoxO4
Histone

9272
2967
2964
MF20
Sc-304
Sc-576
2946
4135
41315
610243
2946
Sc-6246
Sc-99
06-984
07-403
A6403
Ab6046
612244
4642
UCP32-A
Sc-493
sc-7382
Sc-943
9467
9454S
9472
07-371

Company
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Hybridoma Bank
Santa Cruz
Santa Cruz
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
BD Biosciences
Cell Signaling Technology
Santa Cruz
Santa Cruz
Upstate
Millipore
Invitrogen
Abcam
BD Biosciences
Cell Signaling Technology
Alpha Diagnostics
Santa Cruz
Santa Cruz
Santa Cruz
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Upsate

Dilution
1:2000
1:1000
1:500-1000
1:10000
1:400
1:400
1:1000
1:2000
1:1000
1:1000
1:1000
1:400
1:400
1:2000
1:1000
1:1000
1:2000
1:500
1:1000
1:1000
1:400
1:400
1:400
1:1000
1:1000
1:1000
1:3000

SUPPLEMENTAL DATA

Peterson 188

IMMUNOPRECIPITATION
Bax and Bcl-2 binding.

To determine if Bax to Bcl-2 binding corresponded to Akt Ser473 phosphorylation, FFA treated
myotubes were serum starved for two hours with or without the addition FFAs or a commercially
available Akt inhibitor (124005, Calbiochem, Germany). 1% FBS was reintroduced to the media
10 minutes before collection of the myotubes. Similarly, to determine if the binding of Bax to
Bcl-2 was altered with palmitate treatment, Bcl-2 was immunoprecipitated and the binding of
Bax was determined through immunoblot analysis.
After treatment, myotubes were harvested in CHAPS buffer (40 mM HEPES, pH 7.5, 120
mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM -glycerolphosphate, 40 mM NaF, 1.5
mM sodium vanadate, 0.3% CHAPS, 0.1 mM PMSF, 1 mM benzamidine, and 1 mM DTT),
rocked for 20 min at 4°C and then centrifuged at 1,000 g for 10 min at 4°C. An aliquot from the
resulting supernatant was preserved as total protein. The remaining supernatant was incubated
with anti-Bcl-2 (0.2 µg/100 µl; Santa Cruz), and incubated overnight at 4°C. Prior to analysis, the
immune complexes were collected for 1 h at 4°C with a goat anti-mouse BioMag IgG (Quigen,
310004) beads, blocked with 0.1% nonfat dry milk in CHAPS buffer. The beads were collected
using a magnetic stand and washed with 200 mM CHAPS and 60 mM HEPES. The precipitates
were eluted in 5x SDS sample buffer (250 mM Tris-HCl pH 6.8, 10% SDS, 30% Glycerol, 5%
β-mercaptoethanol and 0.02% bromophenol blue) and then boiled for 5 min. The beads were
collected with a magnetic stand, and the supernatant was collected and subjected to SDS-PAGE.

IMMUNOFLUORESCENT STAINING.
BrdU.
Parafin embedded, 7-µm-thick, muscle cross sections from the loaded and control plantaris
muscles were de-paraffinized in xylene, followed by rehydration in graded ethanol washes, and
then rinsed in distilled H2O. The tissues sections were incubated in an antigen retrieval buffer
(10mM sodium citrate, 0.05% Tween-20, ph 6.0) for 30 minutes at 95ºC, washed in phosphate
buffered saline (PBS) and then blocked in 1.5% goat serum in PBS at 37ºC for 30 min. Sections
were then incubated with an anti-BrdU mouse monoclonal antibody (1:20 dilution, 555627; BD
Pharmingen, San Diego, CA) followed by an anti-mouse Alexa 488 (A21463; Invitrogen, CA).
Negative control experiments were done by omitting the BrdU antibody from the tissue sections.
The basal lamina was identified with primary antibodies to anti-Laminin mouse IgG2a (D18;
Hybridoma Bank) followed by goat anti-mouse IgG2a-R (Santa Cruz Biotechnology, CA). Only
the BrdU positive nuclei within the basal lamina were quantified. The BrdU labeling index were
calculated as: the number of BrdU labeled nuclei. total nuclei-1.100. This provided an index of
satellite cell activation.

PAX7
Pax7 antibody (PAX7; Developmental Studies, Hybridoma Bank, U. Iowa) was used to
determine the number of satellite cells in the control muscles (52). Since the formalin fixation

SUPPLEMENTAL DATA

Peterson 189

interfered with the Pax7 antibody, 7µm cross-sections were obtained from frozen mid-belly
sections of the muscle as previously performed in our laboratory (53). Briefly, the sections were
air dried at room temperature, fixed in ice-cold methanol-acetone (1:1) for 10 minutes, rinsed in
PBS, and permeablized in 0.2% triton-X in 0.1% sodium citrate. Next the sections were
incubated for 30 minutes in 1.5% goat serum at 37ºC in before incubation with Pax7 primary
antibodies, followed by an anti-mouse Alexa 488. The samples were then probed with antiLaminin mouse IgG2a (2E8; Hybridoma Bank) followed by goat anti-mouse IgG2a-R (Santa
Cruz Biotechnology, CA).
D18, developed by Dr. Joshua Sanes, PAX7 antibody, developed by Dr. Atsushi Kawakami, and
2E8, developed by Dr. Eva Engvall, antibodies were obtained from the Developmental Studies
Hybridoma Bank developed under the auspices of the NICHD and maintained by The University
of Iowa, Department of Biological Sciences, Iowa City, IA 52242.

TUNEL.
In situ TdT-mediated dUTP nick end labeling (TUNEL) staining. The nuclei with DNA strand
breaks were assessed using a fluorometric TUNEL detection kit according to the manufacturer’s
instructions for both C2C12 cells and muscle cross sections (1684795; Roche Applied Science,
Indianapolis, IN). For muscle cross sections, 10-μm-thick frozen medial gastrocnemius muscle
cross sections from were cut in a freezing cryostat at -20°C. Tissue sections were air dried at
room temperature, fixed in 4% paraformaldehyde in PBS, pH 7.4, at room temperature for 20
min, permeabilized with 0.2% Triton X-100 in 0.1% sodium citrate at 4°C for 2 min, and
incubated with fluorescein-conjugated TUNEL reaction mixture in a humidified chamber at
37°C for 1 h in the dark. Negative control experiments were done by omitting the TdT enzyme in
the TUNEL reaction mixture on the tissue sections. After TUNEL labeling, the muscle sections
were incubated with an anti-chick laminin mouse monoclonal antibody (for visualizing the basal
lamina, 20 μg/ml, clone 31–2) followed by an anti-mouse (1:200 dilution, C2181) and mounted
with DAPI Vectashield mounting medium. TUNEL- and DAPI-positive nuclei and laminin
staining were examined under a fluorescence microscope, and the captured images were stacked
using a SPOT RT camera (Diagnostic Instruments, Sterling Heights, MI), and SPOT RT
software (Universal Imaging, Downingtown, PA). The numbers of TUNEL and DAPI-positive
nuclei were counted from six random, nonoverlapping fields at an objective magnification of
x40. Only the labeled nuclei that were under the laminin staining were counted, to exclude any
non-muscle nuclei in the sections. Data were expressed as number of TUNEL-positive nuclei per
100 nuclei counted.
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MICROPLATE ASSAYS
Akt/PKB Activity Assay.
To confirm changes to Akt/PKB activity another group of C2C12 myotubes from each
treatment condition were incubated in serum free DMEM for 2 hours with the addition of 100
nM insulin for 10 minutes before collection (46;47). Akt/PKB activity was assessed via
Akt/PKB Kinase Activity Kit (Stressgen, EKS-400A). The change in color was measured at a
wavelength of 405 nm by using a Dynex MRX plate reader controlled through PC software
(Revelation; Dynatech Laboratories, CA, USA). Measurements were performed in duplicate,
with all samples analyzed at the same time. The OD405 reading was then normalized to the
milligrams of protein used in the assay.

Cytochrome c Assay.
The mitochondria free cytoplasmic fraction protein obtained as described previously was
used for analysis of the cytochrome-c released from the mitochondria according to the
manufacture’s instructions (#5265, Medical and Biological Laborotories). The change in color
were monitored at a wavelength of 450 nm using a Dynex MRX plate reader. Measurements
were performed in duplicate with all comparisons performed with the same assay. The
cytochrome c content were expressed as OD450 per milligram of protein.

Fluorometric caspase activity assay.
Activity of the caspase-9, 3, and 8 were analyzed by a commercial caspase assay kit (APO54A-019-KI01, Apotech, Switzerland) according to the manufacturer’s procedure and as
previously performed in our laboratory (54). Caspase-3 and caspase-9 were measured as indices
of mitochondrial induced apoptosis, whereas caspase 8 is a non-mitochondrial dependent
caspase. Briefly, 50 µl of the nuclei-free cytosolic extract (without protease inhibitors) were
incubated in 50 µl of assay buffer (50 mM PIPES, 0.1 mM EDTA, 10% glycerol, 10 mM DTT,
pH 7.2) with 100 µM of the fluorogenic 7-amino-4-trifluoromethyl coumarin (AFC)-conjugated
substrate (Ac-DEVD-AFC, Alexis Corp., San Diego, CA, USA) at 37°C for 2 h. Caspase activity
were accessed using a fluorescent microplate reader at the following wavelengths: caspase-8
excitation 380nm and emission 460nm; caspase-3 & 9 excitation 400nm and emission 505nm.
The microplate were incubated at 37°C for 2-hours with caspase activity determined by
subtracting OD readings at time 2-hour from the initial reading at time 0-hour. Optical density
were normalized to the protein concentration of each muscle sample to provide a caspase activity
index (OD . mg protein-1). Measurements were performed in duplicate.

DNA fragmentation.
A cell death detection ELISA kit (Roche Applied Science, Indianapolis, IN, USA) was used
to quantitatively determine the apoptotic DNA fragmentation by measuring the cytosolic histone-
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associated mono- and oligonucleosomes. The change in optical density (OD) was measured at a
wavelength of 450 nm by using a Dynex MRX plate reader controlled through PC software
(Revelation; Dynatech Laboratories, CA, USA). Measurements were performed in duplicate,
with samples from OZR and LZR analyzed at the same time. The OD450 reading was then
normalized control samples. Measurements were performed in triplicate.

STATISTICAL ANALYSES
Statistical analyses were performed using the SYSTAT 11.0 software package. A one
way Analysis of variance (ANOVA) was performed on the difference in all measured variables.
Statistical significance was accepted at P < 0.05. All data are given as means + standard error.
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